ICH Guidline AHA

AHA/ASA Guideline
Guidelines for the Management of Spontaneous

Intracerebral Hemorrhage
A Guideline for Healthcare Professionals From the American Heart
Association/American Stroke Association
The American Academy of Neurology affirms the value of this guideline as an educational
tool for neurologists.
The American Association of Neurological Surgeons and the Congress of Neurological
Surgeons have reviewed this document and affirm its educational content.
Lewis B. Morgenstern, MD, FAHA, FAAN, Chair;
J. Claude Hemphill III, MD, MAS, FAAN, Vice-Chair; Craig Anderson, MBBS, PhD, FRACP;
Kyra Becker, MD; Joseph P. Broderick, MD, FAHA; E. Sander Connolly, Jr, MD, FAHA;
Steven M. Greenberg, MD, PhD, FAHA, FAAN; James N. Huang, MD; R. Loch Macdonald, MD, PhD;
Steven R. Messé, MD, FAHA; Pamela H. Mitchell, RN, PhD, FAHA, FAAN;
Magdy Selim, MD, PhD, FAHA; Rafael J. Tamargo, MD; on behalf of the American Heart Association
Stroke Council and Council on Cardiovascular Nursing
Purpose—The aim of this guideline is to present current and comprehensive recommendations for the diagnosis and
treatment of acute spontaneous intracerebral hemorrhage.
Methods—A formal literature search of MEDLINE was performed. Data were synthesized with the use of evidence tables.
Writing committee members met by teleconference to discuss data-derived recommendations. The American Heart
Association Stroke Council’s Levels of Evidence grading algorithm was used to grade each recommendation. Prerelease
Downloaded from http://ahajournals.org by on November 12, 2018
review of the draft guideline was performed by 6 expert peer reviewers and by the members of the Stroke Council
Scientific Statements Oversight Committee and Stroke Council Leadership Committee. It is intended that this guideline
be fully updated in 3 years’ time.
Results—Evidence-based guidelines are presented for the care of patients presenting with intracerebral hemorrhage. The
focus was subdivided into diagnosis, hemostasis, blood pressure management, inpatient and nursing management,
preventing medical comorbidities, surgical treatment, outcome prediction, rehabilitation, prevention of recurrence, and
future considerations.
Conclusions—Intracerebral hemorrhage is a serious medical condition for which outcome can be impacted by early,
aggressive care. The guidelines offer a framework for goal-directed treatment of the patient with intracerebral
hemorrhage. (Stroke. 2010;41:2108-2129.)
Key Words: AHA Scientific Statements 䡲 intracerebral hemorrhage 䡲 treatment 䡲 diagnosis
䡲 intracranial pressure 䡲 hydrocephalus 䡲 surgery
The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside
relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required
to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.
This statement was approved by the American Heart Association Science Advisory and Coordinating Committee on May 19, 2010. A copy of the
statement is available at http://www.americanheart.org/presenter.jhtml?identifier⫽3003999 by selecting either the “topic list” link or the “chronological
list” link (No. KB-0044). To purchase additional reprints, call 843-216-2533 or e-mail [email protected].
The American Heart Association requests that this document be cited as follows: Morgenstern LB, Hemphill JC 3rd, Anderson C, Becker K, Broderick
JP, Connolly ES Jr, Greenberg SM, Huang JN, Macdonald RL, Messé SR, Mitchell PH, Selim M, Tamargo RJ; on behalf of the American Heart
Association Stroke Council and Council on Cardiovascular Nursing. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline
for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2010;41:2108 –2129.
Expert peer review of AHA Scientific Statements is conducted at the AHA National Center. For more on AHA statements and guidelines development,
visit http://www.americanheart.org/presenter.jhtml?identifier⫽3023366.
Permissions: Multiple copies, modification, alteration, enhancement, and/or distribution of this document are not permitted without the express
permission of the American Heart Association. Instructions for obtaining permission are located at http://www.americanheart.org/presenter.jhtml?
identifier⫽4431. A link to the “Permission Request Form” appears on the right side of the page.
© 2010 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STR.0b013e3181ec611b
2108
Morgenstern et al Intracerebral Hemorrhage Guideline 2109
S pontaneous, nontraumatic intracerebral hemorrhage (ICH)

is a significant cause of morbidity and mortality throughout
the world. Although much has been made of the lack of a
deterioration is common in the first few hours after ICH
onset. More than 20% of patients will experience a decrease
in the Glasgow Coma Scale (GCS) score of ⱖ2 points
specific targeted therapy, much less is written about the success between the prehospital emergency medical services assess-
and goals of aggressive medical and surgical care for this ment and the initial evaluation in the emergency department
disease. Recent population-based studies suggest that most (ED).7 Among those patients with prehospital neurological
patients present with small ICHs that are readily survivable with decline, the GCS score decreases by an average of 6 points
good medical care.1 This suggests that excellent medical care and the mortality rate is ⬎75%. Further, within the first hour
likely has a potent, direct impact on ICH morbidity and mortality of presentation to a hospital, 15% of patients demonstrate a
now, even before a specific therapy is found. Indeed, as decrease in the GCS score of ⱖ2 points.8 The risk for early
discussed later, the overall aggressiveness of ICH care is directly neurological deterioration and the high rate of poor long-term
related to mortality from this disease.2 One of the purposes of outcomes underscores the need for aggressive early
this guideline, therefore, is to remind clinicians of the impor- management.
tance of their care in determining ICH outcome and to provide
an evidence-based framework for that care. Prehospital Management
In order to make this review brief and readily useful to The primary objective in the prehospital setting is to provide
practicing clinicians, the reader is referred elsewhere for the ventilatory and cardiovascular support and to transport the patient to
details of ICH epidemiology.1,3,4 Similarly, there are many the closest facility prepared to care for patients with acute stroke
ongoing clinical studies throughout the world related to this (see ED Management section that follows). Secondary priorities for
disease. The reader is encouraged to consider referring emergency medical services providers include obtaining a focused
patients to these important efforts, which can be found at history regarding the timing of symptom onset (or the time the
http://www.strokecenter.org/trials/. We will not discuss on- patient was last normal) and information about medical history,
going studies because we cannot cover them all; the focus of medication, and drug use. Finally, emergency medical services
this statement is on currently available therapies. Finally, a providers should provide advance notice to the ED of the impending
recent guideline on pediatric stroke was published5 that arrival of a potential stroke patient so that critical pathways can be
obviates the need to repeat the issues of pediatric ICH here. initiated and consulting services can be alerted. Advance notice by
The last ICH Guidelines were published in 2007,6 and this emergency medical services has been demonstrated to significantly
current article serves to update those guidelines. As such, shorten time to computed tomography (CT) scanning in the ED.9
differences from former recommendations are specified in the
current work. The writing group met by phone to determine ED Management

subcategories to evaluate. These included emergency diagnosis It is of the utmost importance that every ED be prepared to
and assessment of ICH and its causes; hemostasis, blood treat patients with ICH or have a plan for rapid transfer to a
pressure (BP); intracranial pressure (ICP)/fever/glucose/ tertiary care center. The crucial resources necessary to man-
seizures/hydrocephalus; iron; ICP monitors/tissue oxygenation; age patients with ICH include neurology, neuroradiology,
clot removal; intraventricular hemorrhage (IVH); withdrawal of neurosurgery, and critical care facilities including adequately
technological support; prevention of recurrent ICH; nursing trained nurses and physicians. In the ED, appropriate consul-
care; rehab/recovery; future considerations. Each subcategory tative services should be contacted as quickly as possible and
was led by an author with 1 or 2 additional authors making the clinical evaluation should be performed efficiently, with
contributions. Full MEDLINE searches were done of all physicians and nurses working in parallel. Table 4 describes
English-language articles regarding relevant human disease the integral components of the history, physical examination,
treatment. Drafts of summaries and recommendations were and diagnostic studies that should be obtained in the ED.
circulated to the whole writing group for feedback. A conference For patients with ICH, emergency management may in-
call was held to discuss controversial issues. Sections were clude neurosurgical interventions for hematoma evacuation,
revised and merged by the Chair. The resulting draft was sent to external ventricular drainage or invasive monitoring and
the whole writing group for comment. Comments were incor- treatment of ICP, BP management, intubation, and reversal of
porated by the Vice Chair and Chair, and the entire committee coagulopathy. Although many centers have critical pathways
was asked to approve the final draft. Changes to the document developed for the treatment of acute ischemic stroke, few
were made by the Chair and Vice Chair in response to peer have protocols for the management of ICH.18 Such pathways
review, and the document was again sent to the entire writing may allow for more efficient, standardized, and integrated
group for suggested changes and approval. Recommendations management of critically ill patients with ICH.
follow the American Heart Association Stroke Council’s
methods of classifying the level of certainty of the treatment Neuroimaging
effect and the class of evidence (Tables 1 and 2). All Class I The abrupt onset of focal neurological symptoms is presumed to
recommendations are listed in Table 3. be vascular in origin until proven otherwise. However, it is
impossible to know whether symptoms are due to ischemia or
Emergency Diagnosis and Assessment of ICH hemorrhage based on clinical characteristics alone. Vomiting,
and Its Causes systolic BP ⬎220 mm Hg, severe headache, coma or decreased
ICH is a medical emergency. Rapid diagnosis and attentive level of consciousness, and progression over minutes or hours all
management of patients with ICH is crucial because early suggest ICH, although none of these findings are specific;
2110 Stroke September 2010
Table 1. Applying Classification of Recommendations and Level of Evidence

*Data available from clinical trials or registries about the usefulness/efficacy in different subpopulations, such as sex, age, history of diabetes, history of prior
myocardial infarction, history of heart failure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply that the recommendation is weak.
Many important clinical questions addressed in the guidelines do not lend themselves to clinical trials. Even though randomized trials are not available, there may
be a very clear clinical consensus that a particular test or therapy is useful or effective.
†In 2003, the ACCF/AHA Task Force on Practice Guidelines developed a list of suggested phrases to use when writing recommendations. All guideline
recommendations have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from
the rest of the document (including headings above sets of recommendations), would still convey the full intent of the recommendation. It is hoped that this will
increase readers’ comprehension of the guidelines and will allow queries at the individual recommendation level.
neuroimaging is thus mandatory.19 CT and magnetic resonance follow-up CT.8,25 Hematoma expansion is predictive of
imaging (MRI) are both reasonable for initial evaluation. CT is clinical deterioration and increased morbidity and mortali-
very sensitive for identifying acute hemorrhage and is consid- ty.8,10,15,25 As such, identifying patients at risk for hematoma
ered the gold standard; gradient echo and T2*susceptibility- expansion is an active area of research. CT angiography and
weighted MRI are as sensitive as CT for detection of acute blood contrast-enhanced CT may identify patients at high risk of
and are more sensitive for identification of prior hemorrhage.20,21 ICH expansion based on the presence of contrast extravasa-
Time, cost, proximity to the ED, patient tolerance, clinical status, tion within the hematoma.26 –30 MRI/angiogram/venogram
and MRI availability may, however, preclude emergent MRI in and CT angiogram/venogram are reasonably sensitive at
a sizeable proportion of cases.22 identifying secondary causes of hemorrhage, including arte-
The high rate of early neurological deterioration after ICH is riovenous malformations, tumors, moyamoya, and cerebral
in part related to active bleeding that may proceed for hours after vein thrombosis.31–33 A catheter angiogram may be consid-
symptom onset. The earlier time from symptom onset to first ered if clinical suspicion is high or noninvasive studies are
neuroimage, the more likely subsequent neuroimages will suggestive of an underlying vascular cause. Clinical suspicion
demonstrate hematoma expansion.15,23,24 Among patients of a secondary cause of ICH may include a prodrome of
undergoing head CT within 3 hours of ICH onset, 28% to headache, neurological, or constitutional symptoms. Radio-
38% have hematoma expansion of greater than one third on logical suspicions of secondary causes of ICH should be
Table 2. Definition of Classes and Levels of Evidence Used in useful to evaluate for underlying structural lesions,
American Heart Association Stroke Council Recommendations including vascular malformations and tumors when
there is clinical or radiological suspicion (Class IIa;
Class I Conditions for which there is evidence for
Level of Evidence: B). (New recommendation)
and/or general agreement that the
procedure or treatment is useful and
effective Medical Treatment for ICH
Class II Conditions for which there is conflicting Hemostasis/Antiplatelets/Deep Vein
evidence and/or a divergence of Thrombosis Prophylaxis
opinion about the usefulness/efficacy Underlying hemostatic abnormalities can contribute to ICH.
of a procedure or treatment Patients at risk include those on oral anticoagulants (OACs),
Class IIa The weight of evidence or opinion is in those with acquired or congenital coagulation factor deficien-
favor of the procedure or treatment cies, and those with qualitative or quantitative platelet abnormal-
Class IIb Usefulness/efficacy is less well ities. Patients undergoing treatment with OACs constitute 12%
established by evidence or opinion to 14% of patients with ICH,34,35 and with increased use of
Class III Conditions for which there is evidence warfarin, the proportion appears to be increasing.36 Recognition
and/or general agreement that the
of an underlying coagulopathy thus provides an opportunity to
procedure or treatment is not
useful/effective and in some cases
target correction in the treatment strategy. For patients with a
may be harmful coagulation factor deficiency and thrombocytopenia, replace-
Therapeutic recommendations
ment of the appropriate factor or platelets is indicated.
For patients being treated with OACs who have life-threatening
Level of Evidence A Data derived from multiple randomized
clinical trials or meta-analyses
bleeding, such as intracranial hemorrhage, the general recommen-
dation is to correct the international normalized ratio (INR) as
Level of Evidence B Data derived from a single randomized
trial or nonrandomized studies
rapidly as possible.37,38 Infusions of vitamin K and fresh-frozen
plasma (FFP) have historically been recommended, but more
Level of Evidence C Consensus opinion of experts, case
studies, or standard of care recently, prothrombin complex concentrates (PCCs) and recom-
binant factor VIIa (rFVIIa) have emerged as potential therapies.
Diagnostic recommendations
Vitamin K remains an adjunct to more rapidly acting initial
Level of Evidence A Data derived from multiple prospective
therapy for life-threatening OAC-associated hemorrhage be-
cohort studies using a reference
standard applied by a masked cause even when given intravenously, it requires hours to correct
evaluator the INR.39 – 41 The efficacy of FFP is limited by risk of allergic

Level of Evidence B Data derived from a single grade A study, and infectious transfusion reactions, processing time, and the
or one or more case-control studies, or volume required for correction. Likelihood of INR correction at
studies using a reference standard 24 hours was linked to time to FFP administration in 1 study,
applied by an unmasked evaluator although 17% of patients still did not have an INR ⱕ1.4 at this
Level of Evidence C Consensus opinion of experts time, suggesting that FFP administered in this manner may be
insufficient for rapid correction of coagulopathy.42
PCCs are plasma-derived factor concentrates primarily
invoked by the presence of subarachnoid hemorrhage, un-
used to treat factor IX deficiency. Because PCCs also contain
usual (noncircular) hematoma shape, the presence of edema
factors II, VII, and X in addition to IX, they are increasingly
out of proportion to the early time an ICH is first imaged, an
recommended for warfarin reversal. PCCs have the advan-
unusual location for hemorrhage, and the presence of other
tages of rapid reconstitution and administration, having high
abnormal structures in the brain like a mass. An MR or CT
concentrations of coagulation factors in small volumes, and
venogram should be performed if hemorrhage location, rela-
processing to inactivate infectious agents. Though different
tive edema volume, or abnormal signal in the cerebral sinuses
PCC preparations differ in relative amounts of factors (with
on routine neuroimaging suggest cerebral vein thrombosis.
VII the most likely to be low), several studies have shown
In summary, ICH is a medical emergency, characterized by high that PCCs can rapidly normalize INR (within minutes) in
morbidity and mortality, which should be promptly diagnosed and patients taking OACs (reviewed in43– 45). Nonrandomized
aggressively managed. Hematoma expansion and early deteriora- retrospective reviews and a small case-control study have
tion are common within the first few hours after onset. shown more rapid correction of INR with vitamin K and PCC
than vitamin K and FFP, but have not revealed a difference in
Recommendations clinical outcome.46 – 48 One randomized trial compared the use
1. Rapid neuroimaging with CT or MRI is recommended
of a PCC (Konyne) to supplement FFP versus FFP alone in
to distinguish ischemic stroke from ICH (Class I; Level
patients with OAC-related ICH, finding that those who
of Evidence: A). (Unchanged from the previous guideline)
2. CT angiography and contrast-enhanced CT may be received PCC had significantly shorter time to INR correction
considered to help identify patients at risk for hema- and received less volume of FFP. Although there was no
toma expansion (Class IIb; Level of Evidence: B), and difference in outcome, those who received FFP also had more
CT angiography, CT venography, contrast-enhanced adverse events, primarily attributable to fluid overload.49
CT, contrast-enhanced MRI, magnetic resonance an- Although PCCs may theoretically increase the risk of throm-
giography, and magnetic resonance venography can be botic complications, this risk appears relatively low.43 De-
Table 3. Class I Recommendations

Recommendations Class/Level of Evidence
Emergency diagnosis and assessment of ICH and Rapid neuroimaging with CT or MRI is recommended to distinguish Class I, Level A
its causes ischemic stroke from ICH. (Unchanged from the previous
guideline)
Medical treatment for ICH Patients with a severe coagulation factor deficiency or severe Class I, Level C
thrombocytopenia should receive appropriate factor replacement
therapy or platelets, respectively. (New recommendation)
Hemostasis/antiplatelets/DVT prophylaxis Patients with ICH whose INR is elevated due to OAC should have Class I, Level C
their warfarin withheld, receive therapy to replace vitamin
K–dependent factors and correct the INR, and receive
intravenous vitamin K. (Revised from the previous guideline)
Patients with ICH should have intermittent pneumatic compression Class I, Level B
for prevention of venous thromboembolism in addition to elastic
stockings. (Unchanged from the previous guideline)
Inpatient management and prevention of
secondary brain injury
General monitoring Initial monitoring and management of ICH patients should take Class I, Level B
place in an intensive care unit, preferably one with physician
and nursing neuroscience intensive care expertise. (Unchanged
from the previous guideline)
Management of glucose Glucose should be monitored and normoglycemia is recommended Class I, Level C
Seizures and antiepileptic drugs Patients with clinical seizures should be treated with antiepileptic Class I, Level A
drugs. (Revised from previous guideline)
Patients with a change in mental status who are found to have Class I, Level C
electrographic seizures on EEG should be treated with
antiepileptic drugs
Procedures/surgery—clot removal Patients with cerebellar hemorrhage who are deteriorating Class I, Level B
neurologically or who have brainstem compression and/or
hydrocephalus from ventricular obstruction should undergo
surgical removal of the hemorrhage as soon as possible.

(Revised from the previous guideline)
Prevention of recurrent ICH After the acute ICH, absent medical contraindications, BP should Class I, Level A
be well controlled, particularly for patients with ICH location
typical of hypertensive vasculopathy. (New recommendation)
CT indicates computed tomography; MRI, magnetic resonance imaging; DVT, deep vein thrombosis; INR, international normalized ratio; OAC, oral anticoagulants;
and EEG, electroencephalogram.
spite the lack of large, well-controlled, randomized trials, (7% versus 2%).60 A subsequent phase 3 study comparing
PCCs are being increasingly recommended as an option in placebo with 20 ␮g/kg and 80 ␮g/kg of rFVIIa failed to show
guidelines promulgated for warfarin reversal in the setting differences in clinical outcome, despite confirming the ability
of OAC-associated life-threatening or intracranial hemor- of both doses to diminish hematoma enlargement.61 Although
rhages.37,38,50 –52 Table 5 provides a list of several products overall serious thromboembolic adverse events were similar,
for factor replacement in warfarin reversal that are commer- the higher rFVIIa (80 ␮g/kg) group had significantly more
cially available in the United States at the present time. arterial events than the placebo group. The authors noted
rFVIIa, licensed to treat hemophilia patients with high titer imbalances in the treatment groups, particularly the greater
inhibitors or congenital factor VII deficiency, has garnered number of patients with IVH in the higher-dose rFVIIa
attention as a potential treatment for spontaneous and OAC- group.60 It remains to be determined whether rFVIIa will
associated ICH. Although rFVIIa can rapidly normalize INR benefit a particular subset of patients with ICH, but currently
in the setting of OAC-associated ICH,53–57 it does not its benefits in ICH patients, whether or not they are under-
replenish all of the vitamin K– dependent factors and there- going treatment with OACs, remain unproven.
fore may not restore thrombin generation as well as PCCs.58 Studies of the effect of prior antiplatelet agent use or
In light of the limited data, a recent American Society of platelet dysfunction on ICH hematoma growth and outcome
Hematology evidence-based review recommended against have found conflicting results. Reported antiplatelet agent use
routine use of rFVIIa for warfarin reversal.59 was not associated with hematoma expansion or clinical
rFVIIa has also been tested in patients with non-OAC ICH. outcome in the placebo group of an ICH neuroprotective
A phase 2 randomized trial showed that treatment with study.62 However, others have suggested that platelet dys-
rFVIIa within 4 hours after ICH onset limited hematoma function as measured by platelet function assays may be
growth and improved clinical outcomes relative to placebo, associated with hematoma expansion and clinical out-
though with increased frequency of thromboembolic events come.63,64 The utility and safety of platelet transfusion or
Table 4. Integral Components of the History, Physical Table 4. Continued

Examination, and Work-Up of the Patient With ICH in the ED
Comments
Comments Toxicology screen in young Cocaine and other sympathomimetic
History or middle-aged patients to drugs are associated with ICH
Time of symptom onset (or detect cocaine and other
time the patient was last sympathomimetic drugs of
normal) abuse
Initial symptoms and Urinalysis and urine culture

progression of symptoms and a pregnancy test in a
woman of childbearing age
Vascular risk factors Hypertension, diabetes,
hypercholesterolemia, and smoking Other routine tests
Medications Anticoagulants, antiplatelet agents, ECG To assess for active coronary ischemia or
decongestants, antihypertensive prior cardiac injury that may indicate
medications, stimulants (including diet poor cardiac function and to obtain a
pills), sympathomimetics baseline in the event of
cardiopulmonary issues during
Recent trauma or surgery Carotid endarterectomy or carotid stenting hospitalization
in particular, as ICH may be related to
hyperperfusion after such procedures Chest radiograph
Dementia Associated with amyloid angiopathy Neuroimaging As described in the text
Alcohol or illicit drug use Cocaine and other sympathomimetic GCS indicates Glasgow Coma Scale; ECG, electrocardiogram.
drugs are associated with ICH,
stimulants
other agents in patients with a normal platelet count, but use
Seizures of antiplatelet agents or platelet dysfunction, is not known.
Liver disease May be associated with coagulopathy Patients with ICH have a high risk of thromboembolic
Cancer and hematologic May be associated with coagulopathy disease.65 Women and African Americans appear to be at greater
disorders risk.65– 67 Intermittent pneumatic compression combined with
Physical examination elastic stockings has been shown by a randomized trial to be
Vital signs Fever is associated with early neurologic superior to elastic stockings alone in reducing occurrence of
deterioration10 asymptomatic deep vein thrombosis after ICH (4.7% versus
Higher initial blood pressure is associated 15.9%).68 Graduated compression stockings alone are ineffec-
with early neurologic deterioration and tive in preventing deep vein thrombosis.69 Less clear, however, is
increased mortality11 the role of adding anticoagulation to pneumatic compression. Two
A general physical small randomized studies found no difference in deep vein throm-
examination focusing on
bosis incidence, and no increase in bleeding, in patients given low-
the head, heart, lungs,
abdomen, and extremities dose subcutaneous heparin initiated at day 4 or at day 10 after
ICH.70,71 An uncontrolled study of treatment initiated on day 2
A thorough but time-urgent A structured examination such as the
neurologic examination National Institutes of Health Stroke found a reduction in thromboembolic disease without increased
Scale can be completed in minutes and rebleeding.70
provides a quantification that allows
easy communication of the severity of Recommendations
the event to other caregivers. GCS 1. Patients with a severe coagulation factor deficiency or
score is similarly well known and severe thrombocytopenia should receive appropriate fac-
easily computed, and the initial GCS tor replacement therapy or platelets, respectively (Class I;
score is a strong predictor of long-term
Level of Evidence: C). (New recommendation)
outcome.12,13 These can be
2. Patients with ICH whose INR is elevated due to OACs
supplemented as needed
should have their warfarin withheld, receive therapy to
Serum and urine tests replace vitamin K– dependent factors and correct the
Complete blood count, Higher creatinine is associated with INR, and receive intravenous vitamin K (Class I; Level
electrolytes, blood urea hematoma expansion. Higher serum of Evidence: C). PCCs have not shown improved
nitrogen and creatinine, glucose is associated with hematoma outcome compared with FFP but may have fewer
and glucose expansion and worse outcome complications compared with FFP and are reasonable
(although there are no data to suggest
to consider as an alternative to FFP (Class IIa; Level of
that normalization improves
Evidence: B). rFVIIa does not replace all clotting
outcome)11,14
factors, and although the INR may be lowered, clotting
Prothrombin time or INR Warfarin-related hemorrhages are may not be restored in vivo; therefore, rFVIIa is not
and an activated partial associated with an increased
routinely recommended as a sole agent for OAC re-
thromboplastin time hematoma volume, greater risk of
versal in ICH (Class III; Level of Evidence: C). (Revised
expansion, and increased morbidity and
mortality15–17
from the previous guideline).
3. Although rFVIIa can limit the extent of hematoma
(Continued)
expansion in noncoagulopathic ICH patients, there
Table 5. Products Commercially Available in the United States for Coagulation Factor Replacement
Dose (Consultation With a Hematologist
Product Factor(s) Is Recommended for Specific Dosing) Uses
Fresh-frozen plasma I (fibrinogen), II, V, VII, IX, X, XI, 10 –15 mL/kg with ideal recovery OAC reversal
XIII, antithrombin would raise factor levels 15%–20% Consumptive coagulopathy
Hepatic dysfunction
Cryoprecipitate I, VIII, XIII, vWF 1–2 U/10 kg Hypo/a-fibrinogenemia
Lack of factor-specific products for
factor VIII deficiency or vWD
Factor XIII deficiency
Prothrombin complex II, IX, X (small amounts of VII) Assayed in factor IX activity Factor IX deficiency (hemophilia B)
concentrates
Bebulin VH (Baxter), Profilnine Both Bebulin and Profilnine are OAC reversal (not FDA-approved)
SD (Grifols) 3-factor PCCs that have
approximately 1/10th the factor VII
activity relative to factor IX activity.
The amounts of factor II and X
relative to IX is variable, but for
Bebulin X⬎II⬎IX and for Profilnine
II⬎X⬃IX
Dosing for factor IX deficiency—
1 U/kg raises activity by 1%
Dosing for OAC reversal has not been
well established
NovoSeven RT (Novo Nordisk) Recombinant activated VII Higher risk of thromboembolic Factor VIII or IX deficiency with inhibitors
complications with higher doses to factor VIII or IX
For hemophilia A or B patients with Congenital factor VII deficiency
inhibitors, 90 ␮g/kg every 2 h Not recommended for spontaneous ICH
For factor VII–deficient patients, 15–30 or OAC reversal
␮g/kg every 4–6 h
Factor VIII concentrates VIII Each factor VIII unit/kg raises the Factor VIII deficiency (hemophilia A)
Plasma-derived serum factor VIII level by 2%

Alphanate (Grifols)*† (typically, a 50-U/kg dose is used to
Humate-P (CSL-Behring)*† raise the factor VIII level to 100%)
Koate-DVI (Bayer)*
Wilate (Octapharma)*† Wilate is not indicated for hemophilia A.
Immunoaffinity purified
Hemofil-M (Baxter)
Monarc-M (Baxter)
Monoclate-P (CSL-Behring)
Recombinant
Advate (Baxter)
Helixate FS (CSL-Behring)
Kogenate FS (Bayer)
Recombinate (Baxter)
Xyntha (Wyeth)
Factor IX concentrates IX Each Factor IX unit/kg raises the Factor IX deficiency (hemophilia B)
Plasma-derived serum level by 1% (typically, a
AlphaNine SD (Grifols) 100-U/kg dose is used to raise the
Mononine (Baxter) level to 100%)
Recombinant
BeneFix (Wyeth) One unit of BeneFix raises the serum
level by ⬇0.83%, so 120 U/kg raises
the activity to 100%.
vWD indicates von Willebrand disease; FDA, US Food and Drug Administration; and PCCs, prothrombin complex concentrates.
*Also contains von Willebrand factor.
†Indicated for von Willebrand disease (dose by ristocetin cofactor units; ratio of fVIII to ristocetin cofactor unit varies by product).
is an increase in thromboembolic risk with rFVIIa from this therapy is needed before any recommenda-
and no clear clinical benefit in unselected patients. tion for its use can be made.
Thus rFVIIa is not recommended in unselected 4. The usefulness of platelet transfusions in ICH pa-
patients. (Class III; Level of Evidence: A). (New tients with a history of antiplatelet use is unclear and
recommendation) Further research to determine is considered investigational (Class IIb; Level of
whether any selected group of patients may benefit Evidence: B). (New recommendation)
5. Patients with ICH should have intermittent pneu- Table 6. Suggested Recommended Guidelines for Treating
matic compression for prevention of venous throm- Elevated BP in Spontaneous ICH
boembolism in addition to elastic stockings (Class I;
1. If SBP is ⬎200 mm Hg or MAP is ⬎150 mm Hg, then consider
Level of Evidence: B). (Unchanged from the previous aggressive reduction of BP with continuous intravenous infusion, with
guideline) frequent BP monitoring every 5 min.
6. After documentation of cessation of bleeding, low-
2. If SBP is ⬎180 mm Hg or MAP is ⬎130 mm Hg and there is the
dose subcutaneous low-molecular-weight heparin or
possibility of elevated ICP, then consider monitoring ICP and reducing BP
unfractionated heparin may be considered for pre- using intermittent or continuous intravenous medications while
vention of venous thromboembolism in patients with maintaining a cerebral perfusion pressure ⱖ60 mm Hg.
lack of mobility after 1 to 4 days from onset (Class
3. If SBP is ⬎180 mm Hg or MAP is ⬎130 mm Hg and there is not
IIb; Level of Evidence: B). (Revised from the previous
evidence of elevated ICP, then consider a modest reduction of BP (eg,
guideline) MAP of 110 mm Hg or target BP of 160/90 mm Hg) using intermittent or
continuous intravenous medications to control BP and clinically
Blood Pressure reexamine the patient every 15 min.
Blood Pressure and Outcome in ICH Note that these recommendations are Class C. SBP indicates systolic blood
Blood pressure (BP) is frequently, and often markedly, pressure; MAP, mean arterial pressure.
elevated in patients with acute ICH; these elevations in BP
are greater than that seen in patients with ischemic stroke.72,73 and absolute growth in hematoma volumes from baseline to
Although BP generally falls spontaneously within several 24 hours in the intensive treatment group compared with the
days after ICH, high BP persists in a substantial proportion of control group. In addition, there was no excess of neurolog-
patients.72,73 Potential pathophysiologic mechanisms include ical deterioration or other adverse events related to intensive
stress activation of the neuroendocrine system (sympathetic BP lowering, nor were there any differences across several
nervous system, renin-angiotensin axis, or glucocorticoid sys- measures of clinical outcome, including disability and quality
tem) and increased intracranial pressure. Hypertension theoreti- of life between groups, although the trial was not powered to
cally could contribute to hydrostatic expansion of the hematoma, detect such outcomes. The study provides an important proof
peri-hematoma edema, and rebleeding, all of which may con- of concept for early BP lowering in patients with ICH, but the
tribute to adverse outcomes in ICH, although a clear association data are insufficient to recommend a definitive policy. An-
between hypertension within the first few hours after ICH and other study, the Antihypertensive Treatment in Acute Cere-
the risk of hematoma expansion (or eventual hematoma volume) bral Hemorrhage (ATACH) trial,81 also confirms the feasi-
bility and safety of early rapid BP lowering in ICH.82 This
has not been clearly demonstrated.25,74

A systematic review75 and a recent large multisite study in study used a 4-tier, dose escalation of intravenous
China73 show that a measurement of systolic BP above 140 to nicardipine-based BP lowering in 80 patients with ICH.
150 mm Hg within 12 hours of ICH is associated with more Thus, advances have been made in our knowledge of the
than double the risk of subsequent death or dependency. mechanisms of ICH and the safety of early BP lowering since
Compared with ischemic stroke, where consistent U- or the publication of the 2007 American Heart Association ICH
J-shaped associations between BP levels and poor outcome guidelines. INTERACT and ATACH now represent the best
have been shown,76 only 1 study of ICH has shown a poor available evidence to help guide decisions about BP lowering
outcome at very low systolic BP levels (⬍140 mm Hg).77 For in ICH. Although these studies have shown that intensive BP
both ischemic stroke and possibly ICH, a likely explanation lowering is clinically feasible and potentially safe, the BP
for such association is reverse causation, whereby very low pressure target, duration of therapy, and whether such treat-
BP levels occur disproportionately in more severe cases, so ment improves clinical outcomes remain unclear.
that although low BP levels may be associated with a high
case fatality, it may not in itself be causal.
Recommendations
1. Until ongoing clinical trials of BP intervention for
ICH are completed, physicians must manage BP on
Effects of BP-Lowering Treatments
the basis of the present incomplete efficacy evidence.
The strong observational data cited previously and sophisti-
Current suggested recommendations for target BP
cated neuroimaging studies that fail to identify an ischemic in various situations are listed in Table 6 and may be
penumbra in ICH78 formed the basis for the INTensive Blood considered (Class IIb; Level of Evidence: C). (Un-
Pressure Reduction in Acute Cerebral Hemorrhage Trial changed from the previous guideline)
(INTERACT) pilot study, published in 2008.79 INTERACT 2. In patients presenting with a systolic BP of 150 to
was an open-label, randomized, controlled trial undertaken in 220 mm Hg, acute lowering of systolic BP to
404 mainly Chinese patients who could be assessed, treated, 140 mm Hg is probably safe (Class IIa; Level of
and monitored within 6 hours of the onset of ICH; 203 were Evidence: B). (New recommendation)
randomized to a treatment with locally available intravenous
BP-lowering agents to target a low systolic BP goal of Inpatient Management and Prevention of
140 mm Hg within 1 hour and maintained for at least the next Secondary Brain Injury
24 hours, and 201 were randomized to a more modest systolic General Monitoring
BP target of 180 mm Hg, as recommended in an earlier AHA Patients with ICH are frequently medically and neurologi-
guideline.80 The study showed a trend toward lower relative cally unstable, particularly within the first few days after
onset. Care of ICH patients in a dedicated neuroscience treatment with outcome. Similarly, therapeutic cooling has not
intensive care unit is associated with a lower mortality rate.83 been systematically investigated in ICH patients.
Frequent vital sign checks, neurological assessments, and
continuous cardiopulmonary monitoring including a cycled Seizures and Antiepileptic Drugs
automated BP cuff, electrocardiographic telemetry, and O2 The incidence of clinical seizures within the first 2 weeks after
saturation probe should be standard. Continuous intra-arterial ICH has been reported to range from 2.7% to 17%, with the
BP monitoring should be considered in patients receiving majority occurring at or near onset.96 –100 Studies of continuous
intravenous vasoactive medications. electroencephalography (EEG) have reported electrographic sei-
zures in 28% to 31% of select cohorts of ICH patients, despite
Nursing Care most having received prophylactic anticonvulsants.101,102 In a
The specific nursing care required for ICH patients in large, single-center study, prophylactic antiepileptic drugs did
intensive care units may include (1) surveillance and moni- significantly reduce the number of clinical seizures after lobar
toring of ICP, cerebral perfusion pressure and hemodynamic ICH.98 However, in prospective and population-based
function; (2) titration and implementation of protocols for studies, clinical seizures have not been associated with
management of ICP, BP, mechanical ventilation, fever, and worsened neurological outcome or mortality.97,103,104 The
serum glucose; and (3) prevention of complications of im- clinical impact of subclinical seizures detected on EEG is also
mobility through positioning, airway maintenance, and mo- not clear. A recent analysis from the placebo arm of an ICH
bilization within physiological tolerance. The consensus doc- neuroprotectant study found that patients who received anti-
ument from the Brain Attack Coalition on comprehensive epileptic drugs (primarily phenytoin) without a documented
stroke centers delineates these as specific areas of monitoring seizure were significantly more likely to be dead or disabled
and complication prevention in which nurses should be at 90 days, after adjusting for other established predictors of
trained. This document also recommends that nurses be ICH outcome.105 Another recent single-center observational
trained in detailed assessment of neurological function in- study had similar findings, specifically for phenytoin.106 Thus
cluding standardized scales such as the National Institutes of only clinical seizures or electrographic seizures in patients
Health Stroke Scale, GCS, and the Glasgow Outcome Scale. with a change in mental status should be treated with
In a Canadian study of 49 hospitals that included ICH antiepileptic drugs. Continuous EEG monitoring should be
patients, a higher proportion of registered nurses and better considered in ICH patients with depressed mental status out
nurse–physician communications were independently associ- of proportion to the degree of brain injury. The utility of
ated with lower 30-day mortality even after adjusting for prophylactic anticonvulsant medication remains uncertain.
disease severity, comorbidities, and hospital characteristics.84

Recommendations
Recommendation
1. Initial monitoring and management of ICH patients Management of Glucose
should take place in an intensive care unit with 1. Glucose should be monitored and normoglycemia is
physician and nursing neuroscience intensive care recommended (Class I: Level of Evidence: C). (New
recommendation)
expertise (Class I; Level of Evidence: B). (Unchanged
from the previous guideline) Seizures and Antiepileptic Drugs
1. Clinical seizures should be treated with antiepileptic
Management of Glucose drugs (Class I; Level of Evidence: A). (Revised from
High blood glucose on admission predicts an increased risk of the previous guideline) Continuous EEG monitoring
mortality and poor outcome in patients with and without diabetes is probably indicated in ICH patients with depressed
and ICH.85– 87 A randomized trial showing improved outcomes mental status out of proportion to the degree of
with tight glucose control (range 80 to 110 mg/dL) using insulin brain injury (Class IIa; Level of Evidence: B). Pa-
infusions in mainly surgical critical care patients88 has increased tients with a change in mental status who are found
the use of this therapy. However, more recent studies have to have electrographic seizures on EEG should be
treated with antiepileptic drugs (Class I; Level of
demonstrated increased incidence of systemic and cerebral Evidence: C). Prophylactic anticonvulsant medica-
hypoglycemic events and possibly even increased risk of mor- tion should not be used (Class III; Level of Evidence:
tality in patients treated with this regimen.89 –92 At present the B). (New recommendation)
optimal management of hyperglycemia in ICH and the target
glucose remains to be clarified. Hypoglycemia should be avoided. Iron
Systemic treatment with the iron chelator deferoxamine
Temperature Management ameliorates ICH-induced changes in markers of DNA dam-
Fever worsens outcome in experimental models of brain inju- age, attenuates brain edema, and improves functional recov-
ry.93,94 The incidence of fever after basal ganglionic and lobar ery in rat models of ICH.107–111 A few studies have examined
ICH is high, especially in patients with IVH. In patients the role of iron in ICH patients and reported that high serum
surviving the first 72 hours after hospital admission, the duration ferritin levels are associated with poor outcome after ICH112
of fever is related to outcome and appears to be an independent and correlate with the perihematoma edema volume.113,114
prognostic factor in these patients.95 These data provide a Limiting iron-mediated toxicity is a promising therapeutic
rationale for aggressive treatment to maintain normothermia in target in ICH. Besides chelating iron, deferoxamine exhibits
patients with ICH; however, there are no data linking fever other neuroprotective properties.115 It induces transcription of
Figure. Intracranial pressure treatment

algorithm. CPP indicates cerebral perfu-
sion pressure; CSF, cerebrospinal fluid.
Adapted from Brain Trauma Foundation
Head Injury Guidelines.126 Copyright
2000, Brain Trauma Foundation.
heme oxygenase-1 and inhibits hemoglobin-mediated glutamate ICP monitor insertion and use include infection and intracra-
excitotoxicity and hypoxia inducible factor prolyl hydroxy- nial hemorrhage. In general, the risk of hemorrhage or
lases.116 –119 Further studies in this area are warranted, but no infection is thought to be higher with VC than with paren-
current therapeutic recommendation can be made at present. chymal catheters, although data on these rates are not derived
from patients with ICH, but rather principally from those with
Procedures/Surgery traumatic brain injury or aneurysmal subarachnoid hemor-
ICP Monitoring and Treatment rhage. In a 1997 series of 108 intraparenchymal devices, the
ICP monitoring is often performed in patients with ICH. rate of infection was 2.9% and the rate of intracranial
However, only very limited published data exist regarding the hemorrhage was 2.1% (15.3% in patients with coagulopa-
frequency of elevated ICP and its management in patients thies).123 A direct comparison of the complications associated
with ICH.120,121 There is evidence for differential pressure with each type of monitoring device was reported in a 1993 to
gradients in at least some cases so that ICP may be elevated 1997 series of 536 intracerebral monitoring devices (274 VCs,
in and around the hematoma but not distant from it.122 229 intraparenchymal parenchymal catheters, and 33 other types
Because the usual causes of elevated ICP are hydrocephalus of devices) in which the overall rate of infection was 4% and the
from IVH or mass effect from the hematoma (or surrounding overall rate of intracranial hemorrhage was 3%.124 Before
edema), patients with small hematomas and limited IVH insertion of a monitoring device, the patient’s coagulation status
usually will not require treatment to lower ICP. should be evaluated. Prior use of antiplatelet agents may justify
ICP is measured using devices inserted into the brain platelet transfusion before the procedure, and the use of warfarin
parenchyma, typically at the bedside. Fiberoptic technology may require reversal of coagulopathy before placement. The
can be used in both types of devices. A ventricular catheter decision to use a VC or a parenchymal catheter device should be
(VC) inserted into the lateral ventricle allows for drainage of based on the specific need to drain cerebrospinal fluid in patients
cerebrospinal fluid, which can help reduce ICP in patients with hydrocephalus or trapped ventricle and the balance of
with hydrocephalus. A parenchymal catheter ICP device is monitoring risks with the unknown utility of ICP management in
inserted into the brain parenchyma and allows for monitoring patients with ICH.
of ICP, but not cerebrospinal fluid drainage. The absence of ICP treatment should be directed at the underlying cause,
published studies showing that management of elevated ICP especially if due to hydrocephalus or mass effect from the
impacts on ICH outcome makes the decision whether to hematoma. Because of limited data regarding ICP in ICH,
monitor and treat elevated ICP unclear. Risks associated with management principles for elevated ICP are borrowed from
traumatic brain injury guidelines, which emphasize maintaining Some reports suggest alternative procedures for IVH such
a cerebral perfusion pressure of 50 to 70 mm Hg, depending on as endoscopic surgical evacuation and ventriculostomy,144 –146
the status of cerebral autoregulation125,126 (see Figure). ICH ventriculoperitoneal shunting,147 or lumbar drainage for hy-
patients with a GCS score of ⱕ8, those with clinical evidence of drocephalus.148 Few data exist to support these strategies.
transtentorial herniation, or those with significant IVH or hydro-
cephalus may be considered for ICP monitoring and treatment. Recommendation
Numerous studies have assessed ventricular size and effects 1. Although intraventricular administration of recom-
of enlargement on ICH outcome.127–130 Among 902 patients binant tissue-type plasminogen activator in IVH
with follow-up data randomized into the international Surgical appears to have a fairly low complication rate,
Trial of Intracerebral Hemorrhage (STICH) trial of early hema- efficacy and safety of this treatment is uncertain and
toma evacuation, 377 had IVH and 208 of these had hydroceph- is considered investigational (Class IIb; Level of
alus (23% of all patients, 55% of those with IVH).131 Hydro- Evidence: B). (New recommendation)
cephalus predicted poor outcome in this study, as well as other
previous studies.127 Thus, hydrocephalus is an important cause Clot Removal
of ICH-related morbidity and mortality,1 and treatment should Surgical Treatment of ICH
be considered in patients with decreased level of consciousness. The decision about whether and when to surgically remove
Small case series have described the use of brain tissue ICH remains controversial. The pathophysiology of brain
oxygen and cerebral microdialysis monitoring in patients injury surrounding the hematoma is due to the mechanical
with ICH.132,133 Because of the small numbers of patients and effects of the growing mass of blood as well as the subsequent
limited data, no recommendation can be made regarding the toxic effects of blood in the surrounding brain tissue. Early
use of these technologies at this time. surgery to limit the mechanical compression of brain and the
toxic effects of blood may limit injury, but the surgical risks
Recommendations
in a patient with ongoing bleeding may be greater. In
1. Patients with a GCS score of <8, those with clinical
addition, operative removal of hemorrhage by craniotomy in
evidence of transtentorial herniation, or those with
significant IVH or hydrocephalus might be consid- all but the most superficial hemorrhages involves cutting
ered for ICP monitoring and treatment. A cerebral through uninjured brain. Among the limitations of ICH surgical
perfusion pressure of 50 to 70 mm Hg may be trials is that young and middle-aged patients at risk of herniation
reasonable to maintain depending on the status of from large ICHs were unlikely to be randomized for treatment.
cerebral autoregulation (Class IIb; Level of Evi- Recommendations for these patients are uncertain.
dence: C). (New recommendation)

2. Ventricular drainage as treatment for hydrocepha- Craniotomy by Location of ICH
lus is reasonable in patients with decreased level of Most but not all149 of the randomized trials of surgery for ICH
consciousness (Class IIa; Level of Evidence: B). (New excluded patients with cerebellar ICH, which comprises 10% to
recommendation)
15% of cases. Previous versions of these guidelines6 cited
Intraventricular Hemorrhage nonrandomized studies showing that patients with cerebellar
IVH occurs in 45% of patients with spontaneous ICH.134 IVH ICH larger than 3 cm in diameter or those with brainstem
can be primary (confined to the ventricles) or secondary compression or hydrocephalus had good outcomes with surgery
(originating as an extension of an ICH). Most IVHs are to remove the hematoma, whereas similar patients managed
secondary and are related to hypertensive hemorrhages in- medically did poorly.150 –155 If the hemorrhage is ⬍3 cm in
volving the basal ganglia and the thalamus.134,135 diameter and there is no brainstem compression or hydroceph-
Although inserting a VC should theoretically aid in drainage alus, reasonable outcomes may be achieved without surgery.
of blood and cerebrospinal fluid from the ventricles, VC use Even though randomized trials of cerebellar hematoma evacua-
alone may be ineffective because of difficulty maintaining tion have not been undertaken, the differences in outcome in the
catheter patency and the slow removal of intraventricular earlier studies are such that clinical equipoise does not exist for
blood.136 Thus there has been recent interest in the use of a trial. Furthermore, the use of a VC alone instead of immediate
thrombolytic agents as adjuncts to VC use in the setting of IVH. cerebellar hematoma evacuation is generally considered insuffi-
Animal studies and clinical series reported that intraventricu- cient and is not recommended, especially in patients with
lar administration of fibrinolytic agents, including urokinase, compressed cisterns.155
streptokinase, and recombinant tissue-type plasminogen activa- The STICH trial found that patients with hematomas extend-
tor, in IVH may reduce morbidity and mortality by accelerating ing to within 1 cm of the cortical surface had a trend toward
blood clearance and clot lysis.137–142 Recently the Clot Lysis: more favorable outcome with surgery within 96 hours, although
Evaluating Accelerated Resolution of IVH (CLEAR-IVH) Trial this finding did not reach statistical significance (odds ratio,
prospectively evaluated the safety of open-label doses of intra- 0.69; 95% confidence interval, 0.47 to 1.01).156 Patients with
ventricular recombinant tissue-type plasminogen activator in 52 lobar hemorrhages and a GCS score of 9 to 12 also had a trend
IVH patients. Symptomatic bleeding occurred in 4% and bacte- toward better outcome. Because the benefit of surgery for
rial ventriculitis in 2%, and the 30-day mortality rate was patients with superficial ICH was not statistically significant
17%.143 The efficacy of this treatment requires confirmation after adjusting for multiple testing, the authors recommended
before its use can be recommended outside of a clinical trial. additional clinical trials to confirm this benefit.157
By contrast, patients in the STICH study with an ICH ⬎1 and/or hydrocephalus from ventricular obstruction
cm from the cortical surface or with a GCS score of ⱕ8 should undergo surgical removal of the hemorrhage as
tended to do worse with surgical removal as compared with soon as possible (Class I; Level of Evidence: B). (Revised
medical management. Another study randomized 108 patients from the previous guideline) Initial treatment of these
with supratentorial subcortical or putaminal ICH ⬎30 mL in patients with ventricular drainage alone rather than
volume to craniotomy or medical management within 8 hours of surgical evacuation is not recommended (Class III; Level
onset.158 Good outcome (good recovery or moderate disability of Evidence: C). (New recommendation)
3. For patients presenting with lobar clots >30 mL and
on the Glasgow Outcome Scale at 1 year) was significantly
within 1 cm of the surface, evacuation of supraten-
better in those treated with surgery, but there was no difference torial ICH by standard craniotomy might be consid-
in overall survival. Other randomized trials have had too few ered (Class IIb; Level of Evidence: B). (Revised from
patients to determine outcomes in subgroups by location, ran- the previous guideline)
domized only patients with deep ICH, or did not report these 4. The effectiveness of minimally invasive clot evacua-
results.159 –161 Enthusiasm for surgical evacuation of thalamic tion utilizing either stereotactic or endoscopic aspi-
and pontine ICH has been limited.154,162,163 ration with or without thrombolytic usage is uncer-
tain and is considered investigational (Class IIb;
Minimally Invasive Surgical Removal of ICH Level of Evidence: B). (New recommendation)
If the indications for surgical evacuation of intracerebral 5. Although theoretically attractive, no clear evidence at
hematomas are controversial, the means by which to achieve present indicates that ultra-early removal of supraten-
this evacuation are even less well established. Several groups torial ICH improves functional outcome or mortality
have developed minimally invasive clot removal techniques. rate. Very early craniotomy may be harmful due to
These techniques tend to make use of stereotactic guidance increased risk of recurrent bleeding (Class III; Level of
combined with either thrombolytic-enhanced or endoscopic- Evidence: B). (Revised from the previous guideline)
enhanced aspiration. Both randomized trials of thrombolytic-
enhanced aspiration for subcortical ICH149,161,164 and Outcome Prediction and Withdrawal of
endoscopic-enhanced aspiration165–167 with or without ste- Technological Support
reotaxis have reported increased clot removal and de- Many observational and epidemiological studies have identified a
creased mortality in those subjects treated surgically wide range of factors that are predictive of outcome after acute ICH.
within 12 to 72 hours, but improved functional outcome From these studies numerous outcome prediction models have been
has not been consistently demonstrated. developed for mortality and functional outcome. Features found in
most of these prediction models include individual patient charac-
Timing of Surgery teristics such as the score on the GCS or National Institutes of
One key issue has been the lack of consensus on the time frame Health Stroke Scale, age, hematoma volume and location, and the
of what constitutes early surgery. Clinical studies have reported presence and amount of IVH.12,172–180 No outcome prediction
a wide variability in the timing of surgery, ranging from within model for ICH, however, has considered the impact of care
4 hours up to 96 hours from the onset of symptoms to time of limitations such as do not resuscitate (DNR) orders or withdrawal of
operation.156,158,161,168 Such time variance among the studies has technological support.
made direct comparison and analysis of the impact of surgical Most patients that die from ICH do so during the initial acute
timing difficult. A retrospective Japanese series of surgical hospitalization, and these deaths usually occur in the setting of
removal of 100 putaminal ICHs within 7 hours of onset (60 withdrawal of support due to presumed poor prognosis.181,182
within 3 hours) reported better than expected outcomes.169 Several studies, however, have now identified withdrawal of
However, subsequent randomized trials that treated subjects medical support and other early care limitations, such as DNR
within 12 hours of onset reported mixed results.158,161,168 An orders within the first day of hospitalization, as independent
increased risk of rebleeding was noted in the small trial of outcome predictors.2,183,184 It is likely that current outcome
subjects randomized within 4 hours of onset.170 prediction models as well as more informal methods of early
Trials that randomized patients within 24 hours,171 48 prognostication after ICH are biased by the failure to account for
hours,159,165 72 hours,149,160 and 96 hours156 have also demon- these care limitations. Concern has been raised that decisions by
strated no clear benefit for surgery as compared with initial physicians to limit care early after ICH are resulting in self-
medical management except for improved outcome in the fulfilling prophecies of poor outcome due to inaccurately pessi-
subgroup of patients in the STICH trial with superficial ICH and mistic prognostication and failure to provide initial aggressive
decreased mortality in those patients with subcortical hemor- therapy in severely ill ICH patients who nonetheless still have
rhages treated with minimally invasive methods within 12 to 72 the possibility of favorable outcome.
hours, as noted above. Although a DNR order by definition means that no attempt
at resuscitation should be made in the event that a cardiopul-
Recommendations
monary arrest occurs, in practical use, when administered
1. For most patients with ICH, the usefulness of sur-
early after ICH, it is a proxy for overall lack of aggres-
gery is uncertain (Class IIb; Level of Evidence: C).
(New recommendation) Specific exceptions to this siveness of care.2 This implies that the overall aggressive-
recommendation follow ness of ICH care at a hospital may be critically important
2. Patients with cerebellar hemorrhage who are deteriorat- in determining patients’ outcome, irrespective of specific
ing neurologically or who have brainstem compression individual characteristics.2,83,185
Although prognostication early after ICH may be desired Committee on Prevention, Detection, Evaluation, and Treatment
by physicians, patients, and families, it is currently based on of High Blood Pressure.197
uncertain ground. Given this uncertainty and the potential for Oral anticoagulation is associated with worse ICH out-
self-fulfilling prophecies of poor outcome, great caution come198,199 and increased risk of recurrence,188 raising the
should be undertaken in attempting precise prognostication question of whether the benefits of anticoagulation for prevent-
early after ICH, especially if the purpose is to consider ing thromboembolism outweigh its risks after initial ICH. For a
withdrawal of support or DNR orders.186 Thus, aggressive hypothetical 69-year-old man with nonvalvular atrial fibrillation
guideline-concordant therapy is recommended for all ICH and prior lobar ICH, Markov modeling predicted that long-term
patients who do not have advanced directives specifying that anticoagulation would shorten quality-adjusted survival because
this should not be undertaken. Care limitations such as DNR of the high risk of recurrence after lobar ICH.200 The results for
orders or withdrawal of support should not be recommended anticoagulation after deep hemispheric ICH were less clear-cut
by treating physicians during the first few days after ICH. and varied depending on assumptions about risk of future
thromboembolism or ICH. The effects of antiplatelet agents on
Recommendation ICH recurrence and severity appear to be substantially smaller
1. Aggressive full care early after ICH onset and than for anticoagulation,16,62,189,201 suggesting that antiplatelet
postponement of new DNR orders until at least the treatment may be a safer alternative to anticoagulation after ICH.
second full day of hospitalization is probably recom- Recently, the ACTIVE A (Atrial Fibrillation Clopidogrel Trial
mended (Class IIa; Level of Evidence: B). Patients with Irbesartan for Prevention of Vascular Events–Aspirin)
with preexisting DNR orders are not included in this study reported on a randomized, double-blind study of the safety
recommendation. Current methods of prognostica- and efficacy of adding clopidogrel 75 mg daily to aspirin 75 to
tion in individual patients early after ICH are likely
100 mg daily in patients with high-risk atrial fibrillation and a
biased by failure to account for the influence of
withdrawal of support and early DNR orders. Pa- contraindication to warfarin. Although previous ICH was listed
tients who are given DNR status at any point should as one of the many reasons for study entry, the authors did not report
receive all other appropriate medical and surgical the proportion of subjects with previous ICH, and therefore the
interventions unless otherwise explicitly indicated. study results may not directly apply to those with previous ICH.
(Revised from the previous guideline) Subjects who received clopidogrel added to aspirin had a 0.8% per
year absolute risk reduction of major vascular events at the cost of
Prevention of Recurrent ICH 0.7% per year increase in major bleeding events.202
The recent Stroke Prevention with Aggressive Reductions in
Population-based studies of survivors of a first hemorrhagic

stroke have identified rates of recurrent ICH of 2.1% to 3.7% Cholesterol Levels (SPARCL) study found increased risk of
per patient-year,187,188 substantially higher than these individ- subsequent ICH (unadjusted hazard ratio, 1.68; 95% confidence
uals’ rate of subsequent ischemic stroke. interval, 1.09 to 2.59) among subjects with prior stroke random-
The most consistently identified risk factor for recurrent ICH ized to high-dose atorvastatin.203 It remains unclear whether this
is lobar location of the initial ICH.187,189 This finding likely effect outweighs the benefits of statin treatment in reducing ische-
represents the association of cerebral amyloid angiopathy with mic cardiac and cerebral events in ICH survivors. Frequent alcohol
lobar location and increased recurrence.190,191 Hemorrhage in use (defined in the Greater Cincinnati/Northern Kentucky study as
locations characteristic of hypertensive vasculopathy, such as ⬎2 drinks per day) has been linked to increased ICH risk204 and is
basal ganglia, thalamus, or brainstem,192 also recur, but less therefore reasonable to avoid after ICH. Other behaviors, such as
frequently. Other factors linked to ICH recurrence in some physical exertion, sexual activity, or stress, have not been linked to
studies include older age,188 post-ICH anticoagulation,188 previ- ICH,205 though little systematic data have been reported.
ous hemorrhage before the presenting ICH,191 carriership of the
apolipoprotein E ␧2 or ␧4 alleles,191,193 and greater number of Recommendations
microbleeds on T2*-weighted gradient-echo MRI.194 1. In situations where stratifying a patient’s risk of
Hypertension is the most important currently modifiable risk recurrent ICH may affect other management deci-
factor for prevention of ICH recurrence.195,196 The importance of sions, it is reasonable to consider the following risk
BP control was supported by data from the Perindopril Protec- factors for recurrence: lobar location of the initial
tion Against Recurrent Stroke Study (PROGRESS) showing that ICH, older age, ongoing anticoagulation, presence of
subjects with cerebrovascular disease randomized to perindopril the apolipoprotein E ␧2 or ␧4 alleles, and greater
plus optional indapamide had significantly lower risk of first number of microbleeds on MRI (Class IIa; Level of
ICH (adjusted hazard ratio, 0.44; 95% confidence interval, 0.28 Evidence: B). (New recommendation)
to 0.69) and a similar, though statistically insignificant, reduction 2. After the acute ICH period, absent medical contra-
indications, BP should be well controlled, particu-
in recurrent ICH (adjusted hazard ratio, 0.37; 95% confidence
larly for patients with ICH location typical of hyper-
interval, 0.10 to 1.38).193 Notably, this reduction appeared to tensive vasculopathy (Class I; Level of Evidence: A).
apply to lobar as well as deep hemispheric ICH. Although (New recommendation)
specific data on the optimal BP for reducing ICH recurrence are 3. After the acute ICH period, a goal target of a normal
not available, a reasonable target is a BP ⬍140/90 (or ⬍130/80 BP of <140/90 (<130/80 if diabetes or chronic
in the presence of diabetes or chronic kidney disease) as kidney disease) is reasonable (Class IIa; Level of
suggested by the most recent report from the Joint National Evidence: B). (New recommendation)
4. Avoidance of long-term anticoagulation as treatment rehabilitation should include education for the patient and
for nonvalvular atrial fibrillation is probably recom- caregiver regarding secondary stroke prevention and means to
mended after spontaneous lobar ICH because of the achieve rehabilitation goals. Rehabilitation programs should
relatively high risk of recurrence (Class IIa; Level of consider lifestyle changes, depression, and caregiver burden as
Evidence: B). Anticoagulation after nonlobar ICH important issues to work on with the patient and caregivers.
and antiplatelet therapy after all ICH might be
considered, particularly when there are definite in-
dications for these agents (Class IIb; Level of Evi- Recommendations
dence: B). (Unchanged from the previous guideline) 1. Given the potentially serious nature and complex pat-
5. Avoidance of heavy alcohol use can be beneficial tern of evolving disability, it is reasonable that all
(Class IIa; Level of Evidence: B). There is insufficient patients with ICH have access to multidisciplinary
data to recommend restrictions on use of statin rehabilitation (Class IIa; Level of Evidence: B). Where
agents or physical or sexual activity (Class IIb; Level possible, rehabilitation can be beneficial when begun as
of Evidence: C). (New recommendation) early as possible and continued in the community as
part of a well-coordinated (seamless) program of ac-
celerated hospital discharge and home-based resettle-
Rehabilitation and Recovery ment to promote ongoing recovery (Class IIa; Level of
Knowledge of differences in the natural history of recovery Evidence: B). (New recommendation)
patterns and prognosis for residual disability and functioning
between ICH and ischemic stroke is complicated by the Future Considerations
disproportionately lower rate of ICH compared with ischemic The future of ICH treatment centers on a cluster of targets.
stroke and the lumping of subarachnoid hemorrhage and ICH The first is clearly prevention. Community-based projects to
together in many studies. There are also problems associated reduce BP through healthy lifestyles and medication adher-
with the insensitivity of many of the outcome measures used in ence are likely to be quite successful in reducing ICH
rehabilitation to allow detection of clinically meaningful differ- incidence.212 Animal studies aimed at preventing cerebral
ences between groups. Even so, there is some evidence that amyloid angiopathy show early promise.213,214
patients with ICH make slightly greater and faster gains in Once an ICH has occurred, efforts to mobilize communities to
recovery206 –208 compared with patients with ischemic stroke. facilitate prompt treatment are similar to efforts aimed at acute
In general, recovery is more rapid in the first few weeks but ischemic stroke treatment.215 Advanced imaging currently may
may continue for many months after ICH,208,209 with approxi- identify patients with ongoing bleeding and provides a target for
mately half of all survivors remaining dependent on others for improved patient selection for testing of hemostatic agents.28
activities of daily living.176 However, patients vary in their speed Hemostatic agents’ efficacy must be clearly weighed against
and degree of recovery, and there is no hard rule regarding when potential arterial and venous thrombotic risk.
recovery is over. Cognition, mood, motivation, and social BP control theoretically may reduce hematoma growth
support all influence recovery, and it is difficult to separate and/or reduce cerebral edema. Early studies suggest that a
intrinsic from adaptive recovery. A simple prognostic score randomized controlled BP-lowering study is feasible.79,81
utilizing age, ICH volume and location, level of consciousness at Safety and efficacy remain to be shown in larger studies.
admission, and pre-ICH cognitive impairment has been shown There is active research on interfering with oxidative injury
to predict independence at 90 days.176 Given that ICH is often after ICH. Iron-chelating agents such as deferoxamine are being
located in lobar regions and complicated by intraventricular studied in early-phase trials.107,115 Pathways that center around
extension, some patients with specific cognitive deficits or hypoxia-inducible factors and prolyl hydroxylases offer other
delayed recovery that is disproportionate to the size of the lesion potential targets for intervention centered around oxidative
may require specialized therapy in rehabilitation. stress.216 The role of microglia and macrophages in hematoma
The provision of stroke rehabilitation services has received resolution is getting more attention.217 Autophagy may be a cellular
considerable attention in recent years. In part this represents a process that could be altered to prevent ICH-related cell death.218
need to tailor services to ensure optimal recovery for patients and There are probably many factors that contribute to injury after
in part is due to fiscal pressures on costly health services. Given ICH, including mass effect, toxicity related to blood, and
strong evidence for the benefits of well-organized, multidisci- displacement of underlying tissue. Seemingly, a simple solution
plinary inpatient (stroke unit) care in terms of improved survival, is hematoma removal. To date, however, surgery has not proved
recovery, and returning home compared with conventional to be the panacea for this condition. New efforts utilizing
nondedicated stroke wards,210 efforts have been made to extend minimally invasive surgical techniques that may remove blood’s
this service model of coordinated care into the community. toxic and pressure effects while avoiding the damage caused by
Specifically, early supported hospital discharge and home-based more invasive procedures, as well as new treatments to dissolve and
rehabilitation programs have been shown to be cost-effective,210 drain intraventricular blood, are currently being studied.143,164
whereas home-based therapy in stable patients has been shown Priorities for ICH research have been published and reviewed
to produce comparable outcomes to conventional outpatient extensively.13 An aggressive, collaborative approach to both
rehabilitation.211 The success of these programs depends on basic and clinical research in this field is likely to promote the
caregiver training and support. However, the likely configura- highest yield. In the mean time, it is clear that our ability to
tion of stroke rehabilitation services in any region will depend on prognosticate about ICH is limited,184 and that aggressive care
available resources and funding options. A key portion of now, and hope for the future, are both clearly indicated.
Disclosures
Writing Group Disclosures
Writing Group Other Research Speakers’ Expert Ownership Consultant/Advisory
Member Employment Research Grant Support Bureau/Honoraria Witness Interest Board Other
Lewis B. University of NIH (R01 NS057127) None None None None None Medical adjudication
Morgenstern Michigan Consultant—Safety and board member
Tolerability of Wyeth*
Deferoxamine in Acute
Cerebral Hemorrhage
(generic study drug)*;
NINDS (U01 NS052510)
Co-I (Deferoxamine
therapy for
intracerebral
hemorrhage—animal
translational grant
examining generic
deferoxamine in ICH)†;
NIH (R01 NS38916)
PI—Brain Attack
Surveillance in Corpus
Christi (observational
study of stroke in a
biethnic community)†
Craig Anderson George Institute, The Australian National None Boehringer-Ingelheim*; None None Boehringer-Ingelheim* None
Sydney, Health & Medical Servier*;
Australia Research Council Sanofi-Aventis*
(employer); Senior
Principal Research
Fellowship (632918);
Program Grant
(571281); Project Grant
(INTERACT 2
study—512402) †;
NINDS (IMSIII Trial 1
V01 NSO52220-02;
subaward SRS#19449
SAP-G100121-
1005817)†; FIA
(RO1NS39512 R-01-NS
36695)†
Kyra Becker University of None None None None None None None
Washington
Joseph P. University of NINDS R-01 NS36695 Novo None None None None None
Broderick Cincinnati (Genetic and Nordisk-
Environmental Risk supplies-
Factors for Hemorrhagic Factor VIIa for
Stroke—Co- NINDS-funded
Investigator)†; STOP-IT trial*
NIH/NINDS (P50
SPOTRIAS
NS44283—PI of PPG)†
E. Sander Columbia None None None None None None None
Connolly, Jr University
Steven M. Massachusetts NIH (R01 NS057127, None None None None None None
Greenberg General Hospital Consultant)—Safety
and Tolerability of
Cerebral Hemorrhage
(generic study drug)†
J. Claude University of NIH/NINDS; U10 None None None None Novo Nordisk* None
Hemphill III California at San NS058931 (PI)†;
Francisco (SF-NET: San Francisco
Neurological
Emergencies Trials
Network—national
network for phase III
clinical trials—no
current ICH trials); Novo
Nordisk (PI)†
(Continued)
Writing Group Disclosures Continued

Writing Group Other Research Speakers’ Expert Ownership Consultant/Advisory
Member Employment Research Grant Support Bureau/Honoraria Witness Interest Board Other
James N. University of None Prospective None None None None None
Huang California at San Advate ITI
Francisco Registry (PAIR)
Study sponsored
by Baxter (Local
PI—UCSF)*
R. Loch University of Physicians Services, None None None Edge Actelion None
Macdonald Toronto Inc. Foundation Grant Therapeutics* Pharmaceuticals (study
for study of of subarachnoid
subarachnoid hemorrhage)*
hemorrhage†
Steven R. University of None None Boehringer-Ingelheim* None None None None
Messé Pennsylvania
Pamela H. University of None None None None None None None
Mitchell Washington
Magdy Selim Beth Israel NIH (R01 None None None None None None
NS057127)—Safety
and Tolerability of
Cerebral Hemorrhage
(generic study drug)†
Rafael J. Johns Hopkins None None None None None None None
Tamargo University
This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the
Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person
receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share
of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the
preceding definition.
*Modest.
†Significant.
Reviewer Disclosures
Other
Research Speakers’ Expert Ownership Consultant/Advisory
Reviewer Employment Research Grant Support Bureau/Honoraria Witness Interest Board Other
Tamilyn Bakas Indiana University None None None None None None None
Purdue University
Indianapolis
John Cole University of None None None None None None None
Maryland
Matthew University of None None None None None None None
Flaherty Cincinnati
Academic Health
Center
Karen C. University of NIH-NINDS R01 NS050192 - None Multiple grand rounds, None None Diffussion Pharmaceuticals, AAN as associate
Johnston Virginia GRASP trial† national talks on Inc.*; Remedy editor of neurology
stroke* Pharmaceuticals, Inc.* through July
2009†
Christina University of None None None None None None None
Stewart-Amidei Central Florida
Greg Zipfel Washington None None None None None None None
University
This table represents the relationships of reviewers that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure
Questionnaire, which all reviewers are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more
during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns
$10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.
*Modest.
†Significant.
References W, Sartor K; Kompetenznetzwerk Schlaganfall B5. Stroke magnetic

1. Zahuranec DB, Gonzales NR, Brown DL, Lisabeth LD, Longwell PJ, resonance imaging is accurate in hyperacute intracerebral hemorrhage: a
Eden SV, Smith MA, Garcia NM, Hoff JT, Morgenstern LB. Presenta- multicenter study on the validity of stroke imaging. Stroke. 2004;35:
tion of intracerebral haemorrhage in a community. J Neurol Neurosurg 502–506.
Psychiatry. 2006;77:340 –344. 21. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk
2. Hemphill JC 3rd, Newman J, Zhao S, Johnston SC. Hospital usage of AM, Hill MD, Patronas N, Latour L, Warach S. Magnetic resonance
early do-not-resuscitate orders and outcome after intracerebral hemor- imaging and computed tomography in emergency assessment of patients
rhage. Stroke. 2004;35:1130 –1134. with suspected acute stroke: a prospective comparison. Lancet. 2007;
3. Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, 369:293–298.
Moomaw CJ, Schneider A, Kissela B, Kleindorfer D, Broderick JP. 22. Singer OC, Sitzer M, du Mesnil de Rochemont R, Neumann-Haefelin T.
Racial variations in location and risk of intracerebral hemorrhage. Practical limitations of acute stroke MRI due to patient-related
Stroke. 2005;36:934 –937. problems. Neurology. 2004;62:1848 –1849.
4. Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year 23. Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T. Pre-
survival of intracerebral hemorrhage in a population-based registry. disposing factors to enlargement of spontaneous intracerebral
Stroke. 2009;40:394 –399. hematoma. Stroke. 1997;28:2370 –2375.
5. Roach ES, Golomb MR, Adams R, Biller J, Daniels S, Deveber G, 24. Fujii Y, Takeuchi S, Sasaki O, Minakawa T, Tanaka R. Multivariate
Ferriero D, Jones BV, Kirkham FJ, Scott RM, Smith ER. Management analysis of predictors of hematoma enlargement in spontaneous intra-
of stroke in infants and children: a scientific statement from a Special cerebral hemorrhage. Stroke. 1998;29:1160 –1166.
Writing Group of the American Heart Association Stroke Council and 25. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer
the Council on Cardiovascular Disease in the Young. Stroke. 2008;39: SA, Begtrup K, Steiner T; Recombinant Activated Factor VII Intrace-
2644 –2691. rebral Hemorrhage Trial Investigators. Hematoma growth is a deter-
6. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, minant of mortality and poor outcome after intracerebral hemorrhage.
Mayberg M, Morgenstern L, Ogilvy CS, Vespa P, Zuccarello M. Neurology. 2006;66:1175–1181.
Guidelines for the management of spontaneous intracerebral hemor- 26. Becker KJ, Baxter AB, Bybee HM, Tirschwell DL, Abouelsaad T,
rhage in adults: 2007 update: a guideline from the American Heart Cohen WA. Extravasation of radiographic contrast is an independent
Association/American Stroke Association Stroke Council, High Blood predictor of death in primary intracerebral hemorrhage. Stroke. 1999;
Pressure Research Council, and the Quality of Care and Outcomes in 30:2025–2032.
Research Interdisciplinary Working Group. Stroke. 2007;38:2001–2023. 27. Goldstein JN, Fazen LE, Snider R, Schwab K, Greenberg SM, Smith
7. Moon JS, Janjua N, Ahmed S, Kirmani JF, Harris-Lane P, Jacob M, EE, Lev MH, Rosand J. Contrast extravasation on CT angiography
Ezzeddine MA, Qureshi AI. Prehospital neurologic deterioration in predicts hematoma expansion in intracerebral hemorrhage. Neurology.
patients with intracerebral hemorrhage. Crit Care Med. 2008;36: 2007;68:889 – 894.
172–175. 28. Wada R, Aviv RI, Fox AJ, Sahlas DJ, Gladstone DJ, Tomlinson G,
8. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, Symons SP. CT angiography “spot sign” predicts hematoma expansion
Spilker J, Duldner J, Khoury J. Early hemorrhage growth in patients in acute intracerebral hemorrhage. Stroke. 2007;38:1257–1262.
with intracerebral hemorrhage. Stroke. 1997;28:1–5. 29. Kim J, Smith A, Hemphill JC 3rd, Smith WS, Lu Y, Dillon WP,
9. Abdullah AR, Smith EE, Biddinger PD, Kalenderian D, Schwamm LH. Wintermark M. Contrast extravasation on CT predicts mortality in
Advance hospital notification by EMS in acute stroke is associated with
primary intracerebral hemorrhage. AJNR Am J Neuroradiol. 2008;29:

shorter door-to-computed tomography time and increased likelihood of 520 –525.
administration of tissue-plasminogen activator. Prehosp Emerg Care. 30. Ederies A, Demchuk A, Chia T, Gladstone DJ, Dowlatshahi D, Bendavit
2008;12:426 – 431. G, Wong K, Symons SP, Aviv RI. Postcontrast CT extravasation is
10. Leira R, Dávalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, Castillo associated with hematoma expansion in CTA spot negative patients.
J; Stroke Project, Cerebrovascular Diseases Group of the Spanish Neu- Stroke. 2009;40:1672–1676.
rological Society. Early neurologic deterioration in intracerebral hem- 31. Gazzola S, Aviv RI, Gladstone DJ, Mallia G, Li V, Fox AJ, Symons SP.
orrhage: predictors and associated factors. Neurology. 2004;63:
Vascular and nonvascular mimics of the CT angiography “spot sign” in
461– 467.
patients with secondary intracerebral hemorrhage. Stroke. 2008;39:
11. Tetri S, Juvela S, Saloheimo P, Pyhtinen J, Hillbom M. Hypertension
1177–1183.
and diabetes as predictors of early death after spontaneous intracerebral
32. Nüssel F, Wegmüller H, Huber P. Comparison of magnetic resonance
hemorrhage. J Neurosurg. 2009;110:411– 417.
angiography, magnetic resonance imaging and conventional
12. Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC.
angiography in cerebral arteriovenous malformation. Neuroradiology.
The ICH score: a simple, reliable grading scale for intracerebral hem-
1991;33:56 – 61.
orrhage. Stroke. 2001;32:891– 897.
33. Yoon HK, Shin HJ, Lee M, Byun HS, Na DG, Han BK. MR angiography
13. NINDS ICH Workshop Participants. Priorities for clinical research in
of moyamoya disease before and after encephaloduroarteriosynangiosis.
intracerebral hemorrhage: report from a National Institute of Neuro-
logical Disorders and Stroke workshop. Stroke. 2005;36:e23– e41. AJR Am J Roentgenol. 2000;174:195–200.
14. Broderick JP, Diringer MN, Hill MD, Brun NC, Mayer SA, Steiner T, 34. Rådberg JA, Olsson JE, Rådberg CT. Prognostic parameters in spon-
Skolnick BE, Davis SM; Recombinant Activated Factor VII Intracere- taneous intracerebral hematomas with special reference to anticoagulant
bral Hemorrhage Trial Investigators. Determinants of intracerebral hem- treatment. Stroke. 1991;22:571–576.
orrhage growth: an exploratory analysis. Stroke. 2007;38:1072–1075. 35. Nilsson OG, Lindgren A, Ståhl N, Brandt L, Säveland H. Incidence of
15. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P; CHANT Inves- intracerebral and subarachnoid haemorrhage in southern Sweden.
tigators. Hematoma growth in oral anticoagulant related intracerebral J Neurol Neurosurg Psychiatry. 2000;69:601– 607.
hemorrhage. Stroke. 2008;39:2993–2996. 36. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P,
16. Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, Moomaw CJ, Haverbusch M, Broderick JP. The increasing incidence of
Khatri P, Stettler B, Adeoye O, Moomaw CJ, Broderick JP, Woo D. anticoagulant-associated intracerebral hemorrhage. Neurology. 2007;68:
Warfarin use leads to larger intracerebral hematomas. Neurology. 2008; 116 –121.
71:1084 –1089. 37. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G;
17. Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EF, American College of Chest Physicians. Pharmacology and management
Rabinstein AA. Predictors of outcome in warfarin-related intracerebral of the vitamin K antagonists: American College of Chest Physicians
hemorrhage. Arch Neurol. 2008;65:1320 –1325. Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;
18. Cooper D, Jauch E, Flaherty ML. Critical pathways for the management 133(suppl):160S–198S.
of stroke and intracerebral hemorrhage: a survey of US hospitals. Crit 38. Hanley JP. Warfarin reversal. J Clin Pathol. 2004;57:1132–1139.
Pathw Cardiol. 2007;6:18 –23. 39. Hung A, Singh S, Tait RC. A prospective randomized study to determine
19. Goldstein LB, Simel DL. Is this patient having a stroke? JAMA. 2005; the optimal dose of intravenous vitamin K in reversal of over-
293:2391–2402. warfarinization. Br J Haematol. 2000;109:537–539.
20. Fiebach JB, Schellinger PD, Gass A, Kucinski T, Siebler M, Villringer 40. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D.
A, Olkers P, Hirsch JG, Heiland S, Wilde P, Jansen O, Röther J, Hacke Comparison of oral vs intravenous phytonadione (vitamin K1) in
patients with excessive anticoagulation: a prospective randomized con- 60. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN,
trolled study. Arch Intern Med. 2003;163:2469 –2473. Skolnick BE, Steiner T; Recombinant Activated Factor VII Intracerebral
41. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A com- Hemorrhage Trial Investigators. Recombinant activated factor VII for
parison of the efficacy and rate of response to oral and intravenous acute intracerebral hemorrhage. N Engl J Med. 2005;352:777–785.
Vitamin K in reversal of over-anticoagulation with warfarin. Br J 61. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN,
Haematol. 2001;115:145–149. Skolnick BE, Steiner T; FAST Trial Investigators. Efficacy and safety of
42. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, recombinant activated factor VII for acute intracerebral hemorrhage.
Smith EE, Greenberg SM, Rosand J. Timing of fresh frozen plasma N Engl J Med. 2008;358:2127–2137.
administration and rapid correction of coagulopathy in warfarin-related 62. Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner
intracerebral hemorrhage. Stroke. 2006;37:151–155. SE; CHANT Investigators. Prior antiplatelet use does not affect hem-
43. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin orrhage growth or outcome after ICH. Neurology. 2009;72:1397–1402.
complex concentrates in reversing warfarin anticoagulation: a review of 63. Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok
the literature. Am J Hematol. 2008;83:137–143. BR, Bernstein RA, Alberts MJ, Batjer HH. Reduced platelet activity is
44. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H; associated with early clot growth and worse 3-month outcome after
Beriplex P/N Anticoagulation Reversal Study Group. Prothrombin intracerebral hemorrhage. Stroke. 2009;40:2398 –2401.
complex concentrate (Beriplex P/N) for emergency anticoagulation 64. Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR,
reversal: a prospective multinational clinical trial. J Thromb Haemost. Batjer HH, Bleck TP, Alberts MJ. Platelet activity and outcome after
2008;6:622– 631. intracerebral hemorrhage. Ann Neurol. 2009;65:352–356.
45. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle 65. Gregory PC, Kuhlemeier KV. Prevalence of venous thromboembolism
CE. Prothrombin complex concentrate (Octaplex) in patients requiring in acute hemorrhagic and thromboembolic stroke. Am J Phys Med
immediate reversal of oral anticoagulation. Thromb Res. 2007; Rehabil. 2003;82:364 –369.
121:9 –16. 66. Kawase K, Okazaki S, Toyoda K, Toratani N, Yoshimura S, Kawano H,
46. Fredriksson K, Norrving B, Strömblad LG. Emergency reversal of Nagatsuka K, Matsuo H, Naritomi H, Minematsu K. Sex difference in
anticoagulation after intracerebral hemorrhage. Stroke. 1992;23: the prevalence of deep-vein thrombosis in Japanese patients with acute
972–977. intracerebral hemorrhage. Cerebrovasc Dis. 2009;27:313–319.
47. Cartmill M, Dolan G, Byrne JL, Byrne PO. Prothrombin complex 67. Christensen MC, Dawson J, Vincent C. Risk of thromboembolic com-
concentrate for oral anticoagulant reversal in neurosurgical emergencies. plications after intracerebral hemorrhage according to ethnicity. Adv
Br J Neurosurg. 2000;14:458 – 461. Ther. 2008;25:831– 841.
48. Sjöblom L, Hårdemark HG, Lindgren A, Norrving B, Fahlén M, Sam- 68. Lacut K, Bressollette L, Le Gal G, Etienne E, De Tinteniac A, Renault
uelsson M, Stigendal L, Stockelberg D, Taghavi A, Wallrup L, Wallvik A, Rouhart F, Besson G, Garcia JF, Mottier D, Oger E; VICTORIAh
J. Management and prognostic features of intracerebral hemorrhage (Venous Intermittent Compression and Thrombosis Occurrence Related
during anticoagulant therapy: a Swedish multicenter study. Stroke. 2001; to Intra-cerebral Acute hemorrhage) Investigators. Prevention of venous
32:2567–2574. thrombosis in patients with acute intracerebral hemorrhage. Neurology.
49. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex 2005;65:865– 869.
in warfarin-related intracranial hemorrhage. Neurosurgery. 1999;45: 69. CLOTS Trials Collaboration, Dennis M, Sandercock PA, Reid J,
1113–1118. Graham C, Murray G, Venables G, Rudd A, Bowler G. Effectiveness of
50. Baglin TP, Keeling DM, Watson HG; British Committee for Standards thigh-length graduated compression stockings to reduce the risk of deep
in Haematology. Guidelines on oral anticoagulation (warfarin): third vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised
edition: 2005 update. Br J Haematol. 2006;132:277–285. controlled trial. Lancet. 2009;373:1958 –1965.
51. Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM; 70. Boeer A, Voth E, Henze T, Prange HW. Early heparin therapy
Warfarin Reversal Consensus Group. Warfarin reversal: consensus in patients with spontaneous intracerebral haemorrhage. J Neurol
guidelines, on behalf of the Australasian Society of Thromb Haemost. Neurosurg Psychiatry. 1991;54:466 – 467.
Med J Aust. 2004;181:492– 497. 71. Dickmann U, Voth E, Schicha H, Henze T, Prange H, Emrich D.
52. Steiner T, Kaste M, Forsting M, Mendelow D, Kwiecinski H, Szikora I, Heparin therapy, deep-vein thrombosis and pulmonary embolism after
Juvela S, Marchel A, Chapot R, Cognard C, Unterberg A, Hacke W. intracerebral hemorrhage. Klin Wochenschr. 1988;66:1182–1183.
Recommendations for the management of intracranial haemorrhage: part 72. Qureshi AI, Ezzeddine MA, Nasar A, Suri MF, Kirmani JF, Hussein
I: spontaneous intracerebral haemorrhage: the European Stroke Initiative HM, Divani AA, Reddi AS. Prevalence of elevated blood pressure in
Writing Committee and the Writing Committee for the EUSI Executive 563,704 adult patients with stroke presenting to the ED in the United
Committee. Cerebrovasc Dis. 2006;22:294 –316. States. Am J Emerg Med. 2007;25:32–38.
53. Lin J, Hanigan WC, Tarantino M, Wang J. The use of recombinant 73. Zhang Y, Reilly KH, Tong W, Xu T, Chen J, Bazzano LA, Qiao D, Ju
activated factor VII to reverse warfarin-induced anticoagulation in Z, Chen CS, He J. Blood pressure and clinical outcome among patients
patients with hemorrhages in the central nervous system: preliminary with acute stroke in Inner Mongolia, China. J Hypertens. 2008;26:
findings. J Neurosurg. 2003;98:737–740. 1446 –1452.
54. Veshchev I, Elran H, Salame K. Recombinant coagulation factor VIIa 74. Jauch EC, Lindsell CJ, Adeoye O, Khoury J, Barsan W, Broderick J,
for rapid preoperative correction of warfarin-related coagulopathy in Pancioli A, Brott T. Lack of evidence for an association between
patients with acute subdural hematoma. Med Sci Monit. 2002;8: hemodynamic variables and hematoma growth in spontaneous intrace-
CS98 –CS100. rebral hemorrhage. Stroke. 2006;37:2061–2065.
55. Sørensen B, Johansen P, Nielsen GL, Sørensen JC, Ingerslev J. Reversal 75. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute
of the International Normalized Ratio with recombinant activated factor stroke and subsequent outcome: a systematic review. Hypertension.
VII in central nervous system bleeding during warfarin thrombopro- 2004;43:18 –24.
phylaxis: clinical and biochemical aspects. Blood Coagul Fibrinolysis. 76. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA; IST Collabo-
2003;14:469 – 477. rative Group. Blood pressure and clinical outcomes in the International
56. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Stroke Trial. Stroke. 2002;33:1315–1320.
Czervionke LF, Meschia JF. Recombinant factor VIIa for rapid reversal 77. Vemmos KN, Tsivgoulis G, Spengos K, Zakopoulos N, Synetos A,
of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Manios E, Konstantopoulou P, Mavrikakis M. U-shaped relationship
Proc. 2004;79:1495–1500. between mortality and admission blood pressure in patients with acute
57. Ilyas C, Beyer GM, Dutton RP, Scalea TM, Hess JR. Recombinant stroke. J Intern Med. 2004;255:257–265.
factor VIIa for warfarin-associated intracranial bleeding. J Clin Anesth. 78. Zazulia AR, Diringer MN, Videen TO, Adams RE, Yundt K, Aiyagari
2008;20:276 –279. V, Grubb RL Jr, Powers WJ. Hypoperfusion without ischemia sur-
58. Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin rounding acute intracerebral hemorrhage. J Cereb Blood Flow Metab.
complex concentrate and recombinant activated factor VII on vitamin K 2001;21:804 – 810.
antagonist induced anticoagulation. Thromb Res. 2008;122:117–123. 79. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, Heeley E,
59. Rosovsky RP, Crowther MA. What Is the Evidence for the Off-label Use Skulina C, Parsons MW, Kim JS, Tao QL, Li YC, Jiang JD, Tai LW,
of Recombinant Factor VIIa (rFVIIa) in the Acute Reversal of Warfarin? Zhang JL, Xu E, Cheng Y, Heritier S, Morgenstern LB, Chalmers J;
Hematology Am Soc Hematol Educ Program. 2008:36 –38. INTERACT Investigators. Intensive blood pressure reduction in acute
cerebral haemorrhage trial (INTERACT): a randomised pilot trial. seizures after intracerebral hemorrhage: a factor in progressive midline
Lancet Neurol. 2008;7:391–399. shift and outcome. Neurology. 2003;60:1441–1446.
80. Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta 102. Claassen J, Jetté N, Chum F, Green R, Schmidt M, Choi H, Jirsch J,
J, Kase C, Krieger D, Mayberg M, Tilley B, Zabramski JM, Zuccarello Frontera JA, Connolly ES, Emerson RG, Mayer SA, Hirsch LJ. Elec-
M. Guidelines for the management of spontaneous intracerebral hem- trographic seizures and periodic discharges after intracerebral hemor-
orrhage: a statement for healthcare professionals from a special writing rhage. Neurology. 2007;69:1356 –1365.
group of the Stroke Council, American Heart Association. Stroke. 1999; 103. Andaluz N, Zuccarello M. Recent trends in the treatment of spontaneous
30:905–915. intracerebral hemorrhage: analysis of a nationwide inpatient database.
81. Qureshi AI. Antihypertensive Treatment of Acute Cerebral Hemorrhage J Neurosurg. 2009;110:403– 410.
(ATACH): rationale and design. Neurocritical Care. 2007;6:56 – 66. 104. Szaflarski JP, Rackley AY, Kleindorfer DO, Khoury J, Woo D, Miller
82. Qureshi A. Antihypertensive treatment of acute cerebral hemorrhage R, Alwell K, Broderick JP, Kissela BM. Incidence of seizures in the
(ATACH) trial. Presented at the International Stroke Conference, New acute phase of stroke: a population-based study. Epilepsia. 2008;49:
Orleans, La, February 20 –22, 2008. 974 –981.
83. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical 105. Messé SR, Sansing LH, Cucchiara BL, Herman ST, Lyden PD, Kasner
intensive care unit is associated with reduced mortality rate after intra- SE; CHANT investigators. Prophylactic antiepileptic drug use is asso-
cerebral hemorrhage. Crit Care Med. 2001;29:635– 640. ciated with poor outcome following ICH. Neurocrit Care. 2009;11:
84. Estabrooks CA, Midodzi WK, Cummings GG, Ricker KL, Giovannetti 38 – 44.
P. The impact of hospital nursing characteristics on 30-day mortality. 106. Naidech AM, Garg RK, Liebling S, Levasseur K, Macken MP, Schuele
Nurs Res. 2005;54:74 – 84. SU, Batjer HH. Anticonvulsant use and outcomes after intracerebral
85. Fogelholm R, Murros K, Rissanen A, Avikainen S. Admission blood hemorrhage. Stroke. 2009;40:3810 –3815.
glucose and short term survival in primary intracerebral haemorrhage: a 107. Gu Y, Hua Y, Keep RF, Morgenstern LB, Xi G. Deferoxamine reduces
population based study. J Neurol Neurosurg Psychiatry. 2005;76: intracerebral hematoma-induced iron accumulation and neuronal death
349 –353. in piglets. Stroke. 2009;40:2241–2243.
86. Kimura K, Iguchi Y, Inoue T, Shibazaki K, Matsumoto N, Kobayashi K, 108. Huang FP, Xi G, Keep RF, Hua Y, Nemoianu A, Hoff JT. Brain edema
Yamashita S. Hyperglycemia independently increases the risk of early after experimental intracerebral hemorrhage: role of hemoglobin degra-
death in acute spontaneous intracerebral hemorrhage. J Neurol Sci. dation products. J Neurosurg. 2002;96:287–293.
2007;255:90 –94. 109. Nakamura T, Keep RF, Hua Y, Schallert T, Hoff JT, Xi G. Deferox-
87. Passero S, Ciacci G, Ulivelli M. The influence of diabetes and hyper- amine-induced attenuation of brain edema and neurological deficits in a
glycemia on clinical course after intracerebral hemorrhage. Neurology. rat model of intracerebral hemorrhage. J Neurosurg. 2004;100:672– 678.
2003;61:1351–1356. 110. Okauchi M, Hua Y, Keep RF, Morgenstern LB, Xi G. Effects of
88. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, deferoxamine on intracerebral hemorrhage-induced brain injury in aged
Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. rats. Stroke. 2009;40:1858 –1863.
Intensive insulin therapy in the critically ill patients. N Engl J Med. 111. Wu J, Hua Y, Keep RF, Nakamura T, Hoff JT, Xi G. Iron and iron-
2001;345:1359 –1367. handling proteins in the brain after intracerebral hemorrhage. Stroke.
89. Oddo M, Schmidt JM, Carrera E, Badjatia N, Connolly ES, Presciutti M, 2003;34:2964 –2969.
Ostapkovich ND, Levine JM, Le Roux P, Mayer SA. Impact of tight 112. de la Ossa N, Sobrino T, Silva Y, Trueta J, Girona, Spain Milla M,
glycemic control on cerebral glucose metabolism after severe brain Gomis M, Agulla J, Serena J, Castillo J, Da’ valos A. High serum ferritin
injury: a microdialysis study. Crit Care Med. 2008;36:3233–3238. levels are associated with poor outcome of patients with spontaneous
90. Vespa P, Boonyaputthikul R, McArthur DL, Miller C, Etchepare M, intracerebral hemorrhage. Stroke. 2009;40:e105. Abstract P343.
Bergsneider M, Glenn T, Martin N, Hovda D. Intensive insulin therapy 113. Lou M, Lieb K, Selim M. The relationship between hematoma iron
reduces microdialysis glucose values without altering glucose utilization content and perihematoma edema: an MRI study. Cerebrovasc Dis.
or improving the lactate/pyruvate ratio after traumatic brain injury. Crit 2009;27:266 –271.
Care Med. 2006;34:850 – 856. 114. Mehdiratta M, Kumar S, Hackney D, Schlaug G, Selim M. Association
91. Vespa PM. Intensive glycemic control in traumatic brain injury: what is between serum ferritin level and perihematoma edema volume in
the ideal glucose range? Crit Care. 2008;12:175. patients with spontaneous intracerebral hemorrhage. Stroke. 2008;39:
92. NICE-SUGAR Study Investigators, Finfer S, Chittock DR, Su SY, Blair 1165–1170.
D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, 115. Selim M. Deferoxamine mesylate: a new hope for intracerebral hemor-
Hébert PC, Heritier S, Heyland DK, McArthur C, McDonald E, Mitchell rhage: from bench to clinical trials. Stroke. 2009;40(suppl):S90 –S91.
I, Myburgh JA, Norton R, Potter J, Robinson BG, Ronco JJ. Intensive 116. Ratan RR, Siddiq A, Aminova L, Langley B, McConoughey S,
versus conventional glucose control in critically ill patients. N Engl Karpisheva K, Lee HH, Carmichael T, Kornblum H, Coppola G,
J Med. 2009;360:1283–1297. Geschwind DH, Hoke A, Smirnova N, Rink C, Roy S, Sen C, Beattie
93. Michenfelder JD, Milde JH. The relationship among canine brain tem- MS, Hart RP, Grumet M, Sun D, Freeman RS, Semenza GL, Gazaryan
perature, metabolism, and function during hypothermia. Anesthesiology. I. Small molecule activation of adaptive gene expression: tilorone or its
1991;75:130 –136. analogs are novel potent activators of hypoxia inducible factor-1 that
94. Takagi K. Body temperature in acute stroke. Stroke. 2002;33: provide prophylaxis against stroke and spinal cord injury. Ann N Y Acad
2154 –2155. Sci. 2008;1147:383–394.
95. Schwarz S, Häfner K, Aschoff A, Schwab S. Incidence and prognostic 117. Regan RF, Panter SS. Hemoglobin potentiates excitotoxic injury in
significance of fever following intracerebral hemorrhage. Neurology. cortical cell culture. J Neurotrauma. 1996;13:223–231.
2000;54:354 –361. 118. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, LaManna JC,
96. Berger AR, Lipton RB, Lesser ML, Lantos G, Portenoy RK. Early Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I,
seizures following intracerebral hemorrhage: implications for therapy. Seeley T, Gunzler V, Ratan RR. Hypoxia-inducible factor prolyl
Neurology. 1988;38:1363–1365. 4-hydroxylase inhibition: a target for neuroprotection in the central
97. Bladin CF, Alexandrov AV, Bellavance A, Bornstein N, Chambers B, nervous system. J Biol Chem. 2005;280:41732– 41743.
Coté R, Lebrun L, Pirisi A, Norris JW. Seizures after stroke: a pro- 119. Zaman K, Ryu H, Hall D, O’Donovan K, Lin KI, Miller MP, Marquis
spective multicenter study. Arch Neurol. 2000;57:1617–1622. JC, Baraban JM, Semenza GL, Ratan RR. Protection from oxidative
98. Passero S, Rocchi R, Rossi S, Ulivelli M, Vatti G. Seizures after stress-induced apoptosis in cortical neuronal cultures by iron chelators is
spontaneous supratentorial intracerebral hemorrhage. Epilepsia. 2002; associated with enhanced DNA binding of hypoxia-inducible factor-1
43:1175–1180. and ATF-1/CREB and increased expression of glycolytic enzymes,
99. Sung CY, Chu NS. Epileptic seizures in intracerebral haemorrhage. p21(waf1/cip1), and erythropoietin. J Neurosci. 1999;19:9821–9830.
J Neurol Neurosurg Psychiatry. 1989;52:1273–1276. 120. Fernandes HM, Siddique S, Banister K, Chambers I, Wooldridge T,
100. Yang TM, Lin WC, Chang WN, Ho JT, Wang HC, Tsai NW, Shih YT, Gregson B, Mendelow AD. Continuous monitoring of ICP and CPP
Lu CH. Predictors and outcome of seizures after spontaneous intrace- following ICH and its relationship to clinical, radiological and surgical
rebral hemorrhage. Clinical article. J Neurosurg. 2009;111:87–93. parameters. Acta Neurochir Suppl. 2000;76:463– 466.
101. Vespa PM, O’Phelan K, Shah M, Mirabelli J, Starkman S, Kidwell C, 121. Ziai WC, Torbey MT, Naff NJ, Williams MA, Bullock R, Marmarou A,
Saver J, Nuwer MR, Frazee JG, McArthur DA, Martin NA. Acute Tuhrim S, Schmutzhard E, Pfausler B, Hanley DF. Frequency of sus-
tained intracranial pressure elevation during treatment of severe intra- 143. Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the
ventricular hemorrhage. Cerebrovasc Dis. 2009;27:403– 410. clot lysis evaluating accelerated resolution of intraventricular hemor-
122. Chambers IR, Banister K, Mendelow AD. Intracranial pressure within a rhage (CLEAR-IVH) clinical trial. Acta neurochirurgica. 2008;105:
developing intracerebral haemorrhage. Br J Neurosurg. 2001;15: 217–220.
140 –141. 144. Horváth Z, Veto F, Balás I, K[umlaut]ovér F, Dóczi T. Biportal endo-
123. Martı́nez-Mañas RM, Santamarta D, de Campos JM, Ferrer E. Camino scopic removal of a primary intraventricular hematoma: case report.
intracranial pressure monitor: prospective study of accuracy and com- Minim Invasive Neurosurg. 2000;43:4 – 8.
plications. J Neurol Neurosurg Psychiatry. 2000;69:82– 86. 145. Longatti PL, Martinuzzi A, Fiorindi A, Maistrello L, Carteri A. Neu-
124. Guyot LL, Dowling C, Diaz FG, Michael DB. Cerebral monitoring roendoscopic management of intraventricular hemorrhage. Stroke. 2004;
devices: analysis of complications. Acta Neurochir Suppl. 1998;71: 35:e35– e38.
47– 49. 146. Yadav YR, Mukerji G, Shenoy R, Basoor A, Jain G, Nelson A. Endo-
125. Brain Trauma Foundation; American Association of Neurological Sur- scopic management of hypertensive intraventricular haemorrhage with
geons; Congress of Neurological Surgeons; Joint Section on Neuro- obstructive hydrocephalus. BMC Neurol. 2007;7:1.
trauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, 147. Yilmazlar S, Abas F, Korfali E. Comparison of ventricular drainage in
Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, poor grade patients after intracranial hemorrhage. Neurol Res. 2005;27:
Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons 653– 656.
SD, Ullman JS, Videtta W, Wilberger JE, Wright DW. Guidelines for 148. Huttner HB, Schwab S, Bardutzky J. Lumbar drainage for communi-
the management of severe traumatic brain injury. IX. Cerebral perfusion cating hydrocephalus after ICH with ventricular hemorrhage. Neurocrit
thresholds. J Neurotrauma. 2007;24(suppl 1):S59 –S64. Care. 2006;5:193–196.
126. Management and Prognosis of Severe Traumatic Brain Injury. New 149. Wang WZ, Jiang B, Liu HM, Li D, Lu CZ, Zhao YD, Sander JW.
York, NY: Brain Trauma Foundation; 2000. Minimally invasive craniopuncture therapy vs. conservative treatment
127. Diringer MN, Edwards DF, Zazulia AR. Hydrocephalus: a previously for spontaneous intracerebral hemorrhage: results from a randomized
unrecognized predictor of poor outcome from supratentorial intracere- clinical trial in China. Int J Stroke. 2009;4:11–16.
bral hemorrhage. Stroke. 1998;29:1352–1357. 150. Kase C. Cerebellar hemorrhage. In: Kase C, Caplan L, eds. Intracerebral
128. Huttner HB, Nagel S, Tognoni E, Köhrmann M, Jüttler E, Orakcioglu B, Hemorrhage. Boston: Butterworth-Heinemann; 1994:425–443.
Schellinger PD, Schwab S, Bardutzky J. Intracerebral hemorrhage with 151. Sypert G, Arpin-Sypert E. Spontaneous posterior fossa hematomas. In:
severe ventricular involvement: lumbar drainage for communicating Kaufman H, ed. Intracerebral Hematomas. New York, NY: Raven
hydrocephalus. Stroke. 2007;38:183–187. Press;1992:187–196.
129. van Gijn J, Hijdra A, Wijdicks EF, Vermeulen M, van Crevel H. Acute 152. Da Pian R, Bazzan A, Pasqualin A. Surgical versus medical treatment of
hydrocephalus after aneurysmal subarachnoid hemorrhage. J Neurosurg. spontaneous posterior fossa haematomas: a cooperative study on 205
1985;63:355–362. cases. Neurol Res. 1984;6:145–151.
130. Diringer M, Ladenson PW, Stern BJ, Schleimer J, Hanley DF. Plasma 153. Kirollos RW, Tyagi AK, Ross SA, van Hille PT, Marks PV. Man-
atrial natriuretic factor and subarachnoid hemorrhage. Stroke. 1988;19: agement of spontaneous cerebellar hematomas: a prospective treatment
1119 –1124. protocol. Neurosurgery. 2001;49:1378 –1386.
131. Bhattathiri PS, Gregson B, Prasad KS, Mendelow AD; STICH Investi- 154. Morioka J, Fujii M, Kato S, Fujisawa H, Akimura T, Suzuki M,
gators. Intraventricular hemorrhage and hydrocephalus after spon- Kobayashi S; Japan Standard Stroke Registry Group (JSSR). Surgery for
taneous intracerebral hemorrhage: results from the STICH trial. Acta spontaneous intracerebral hemorrhage has greater remedial value than
Neurochir Suppl. 2006;96:65– 68. conservative therapy. Surg Neurol. 2006;65:67–72.

132. Hemphill JC 3rd, Morabito D, Farrant M, Manley GT. Brain tissue 155. van Loon J, Van Calenbergh F, Goffin J, Plets C. Controversies in the
oxygen monitoring in intracerebral hemorrhage. Neurocrit Care. 2005; management of spontaneous cerebellar haemorrhage: a consecutive
3:260 –270. series of 49 cases and review of the literature. Acta Neurochir (Wien).
133. Miller CM, Vespa PM, McArthur DL, Hirt D, Etchepare M. Frameless 1993;122:187–193.
stereotactic aspiration and thrombolysis of deep intracerebral hemor- 156. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale
rhage is associated with reduced levels of extracellular cerebral glu- GM, Hope DT, Karimi A, Shaw MD, Barer DH; STICH investigators.
tamate and unchanged lactate pyruvate ratios. Neurocrit Care. 2007;6: Early surgery versus initial conservative treatment in patients with
22–29. spontaneous supratentorial intracerebral haematomas in the International
134. Hallevi H, Albright KC, Aronowski J, Barreto AD, Martin-Schild S, Khaja Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised
AM, Gonzales NR, Illoh K, Noser EA, Grotta JC. Intraventricular hemor- trial. Lancet. 2005;365:387–397.
rhage: Anatomic relationships and clinical implications. Neurology. 2008; 157. Kirkman MA, Mahattanakul W, Gregson BA, Mendelow AD. The effect
70:848–852. of the results of the STICH trial on the management of spontaneous
135. Engelhard HH, Andrews CO, Slavin KV, Charbel FT. Current man- supratentorial intracerebral haemorrhage in Newcastle. Br J Neurosurg.
agement of intraventricular hemorrhage. Surg Neurol. 2003;60:15–21. 2008;22:739 –746.
136. Huttner HB, K[umlaut]ohrmann M, Berger C, Georgiadis D, Schwab S. 158. Pantazis G, Tsitsopoulos P, Mihas C, Katsiva V, Stavrianos V, Zymaris
Influence of intraventricular hemorrhage and occlusive hydrocephalus S. Early surgical treatment vs conservative management for spontaneous
on the long-term outcome of treated patients with basal ganglia hemor- supratentorial intracerebral hematomas: a prospective randomized study.
rhage: a case-control study. J Neurosurg. 2006;105:412– 417. Surg Neurol. 2006;66:492–501.
137. Fountas KN, Kapsalaki EZ, Parish DC, Smith B, Smisson HF, Johnston 159. Juvela S, Heiskanen O, Poranen A, Valtonen S, Kuurne T, Kaste M,
KW, Robinson JS. Intraventricular administration of rt-PA in patients Troupp H. The treatment of spontaneous intracerebral hemorrhage: a
with intraventricular hemorrhage. South Med J. 2005;98:767–773. prospective randomized trial of surgical and conservative treatment.
138. Lapointe M, Haines S. Fibrinolytic therapy for intraventricular hemor- J Neurosurg. 1989;70:755–758.
rhage in adults. Cochrane Database Syst Rev. 2002:CD003692. 160. Teernstra OP, Evers SM, Lodder J, Leffers P, Franke CL, Blaauw G;
139. Murry KR, Rhoney DH, Coplin WM. Urokinase in the treatment of Multicenter randomized controlled trial (SICHPA). Stereotactic
intraventricular hemorrhage. Ann Pharmacother. 1998;32:256 –258. treatment of intracerebral hematoma by means of a plasminogen acti-
140. Naff NJ, Hanley DF, Keyl PM, Tuhrim S, Kraut M, Bederson J, Bullock vator: a multicenter randomized controlled trial (SICHPA). Stroke.
R, Mayer SA, Schmutzhard E. Intraventricular thrombolysis speeds 2003;34:968 –974.
blood clot resolution: results of a pilot, prospective, randomized, double- 161. Zuccarello M, Brott T, Derex L, Kothari R, Sauerbeck L, Tew J, Van
blind, controlled trial. Neurosurgery. 2004;54:577–583. Loveren H, Yeh HS, Tomsick T, Pancioli A, Khoury J, Broderick J.
141. Nieuwkamp DJ, de Gans K, Rinkel GJ, Algra A. Treatment and outcome Early surgical treatment for supratentorial intracerebral hemorrhage: a
of severe intraventricular extension in patients with subarachnoid or randomized feasibility study. Stroke. 1999;30:1833–1839.
intracerebral hemorrhage: a systematic review of the literature. J Neurol. 162. Kanaya H, Saiki I, Ohuchi T. Hypertensive ICH in Japan: update on
2000;247:117–121. surgical treatment. In: Mizukami M, Kanaya K, Yamori Y, eds.
142. Pang D, Sclabassi RJ, Horton JA. Lysis of intraventricular blood clot with Hypertensive Intracerebral Hemorrhage. New York, NY: Raven
urokinase in a canine model: part 3: effects of intraventricular urokinase on Press; 1983:147–163.
clot lysis and posthemorrhagic hydrocephalus. Neurosurgery. 1986;19: 163. Kanno T, Sano H, Shinomiya Y, Katada K, Nagata J, Hoshino M,
553–572. Mitsuyama F. Role of surgery in hypertensive intracerebral
hematoma: a comparative study of 305 nonsurgical and 154 surgical evidence-based support for an intensivist-directed specialty ICU model
cases. J Neurosurg. 1984;61:1091–1099. of care. J Neurosurg Anesthesiol. 2001;13:83–92.
164. Morgan T, Zuccarello M, Narayan R, Keyl P, Lane K, Hanley D. 186. Hemphill JC 3rd, White DB. Clinical nihilism in neuroemergencies.
Preliminary findings of the minimally-invasive surgery plus rtPA for Emerg Med Clin North Am. 2009;27:27–37, vii–viii.
intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta 187. Bailey RD, Hart RG, Benavente O, Pearce LA. Recurrent brain hemor-
Neurochir Suppl. 2008;105:147–151. rhage is more frequent than ischemic stroke after intracranial hemor-
165. Auer LM, Deinsberger W, Niederkorn K, Gell G, Kleinert R, Schneider rhage. Neurology. 2001;56:773–777.
G, Holzer P, Bone G, Mokry M, K[umlaut]orner E, et al. Endoscopic 188. Vermeer SE, Algra A, Franke CL, Koudstaal PJ, Rinkel GJ.
surgery versus medical treatment for spontaneous intracerebral Long-term prognosis after recovery from primary intracerebral hem-
hematoma: a randomized study. J Neurosurg. 1989;70:530 –535. orrhage. Neurology. 2002;59:205–209.
166. Cho DY, Chen CC, Chang CS, Lee WY, Tso M. Endoscopic surgery for 189. Viswanathan A, Rakich SM, Engel C, Snider R, Rosand J, Greenberg
spontaneous basal ganglia hemorrhage: comparing endoscopic surgery, SM, Smith EE. Antiplatelet use after intracerebral hemorrhage.
stereotactic aspiration, and craniotomy in noncomatose patients. Surg Neurology. 2006;66:206 –209.
Neurol. 2006;65:547–555. 190. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke.
167. Nishihara T, Morita A, Teraoka A, Kirino T. Endoscopy-guided removal 1987;18:311–324.
of spontaneous intracerebral hemorrhage: comparison with computer 191. O’Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI,
tomography-guided stereotactic evacuation. Childs Nerv Syst. 2007;23: Ikeda D, Greenberg SM. Apolipoprotein E genotype and the risk of
677– 683. recurrent lobar intracerebral hemorrhage. N Engl J Med. 2000;342:
168. Morgenstern LB, Frankowski RF, Shedden P, Pasteur W, Grotta JC. 240 –245.
Surgical treatment for intracerebral hemorrhage (STICH): a single- 192. Fisher CM. Pathological observations in hypertensive cerebral hemor-
center, randomized clinical trial. Neurology. 1998;51:1359 –1363. rhage. J Neuropathol Exp Neurol. 1971;30:536 –550.
169. Kaneko M, Tanaka K, Shimada T, Sato K, Uemura K. Long-term 193. Tzourio C, Arima H, Harrap S, Anderson C, Godin O, Woodward M,
evaluation of ultra-early operation for hypertensive intracerebral hem- Neal B, Bousser MG, Chalmers J, Cambien F, MacMahon S. APOE
orrhage in 100 cases. J Neurosurg. 1983;58:838 – 842. genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology.
170. Morgenstern LB, Demchuk AM, Kim DH, Frankowski RF, Grotta JC. 2008;70:1322–1328.
Rebleeding leads to poor outcome in ultra-early craniotomy for intrace- 194. Greenberg SM, Eng JA, Ning M, Smith EE, Rosand J. Hemorrhage
rebral hemorrhage. Neurology. 2001;56:1294 –1299. burden predicts recurrent intracerebral hemorrhage after lobar hemor-
171. Tan SH, Ng PY, Yeo TT, Wong SH, Ong PL, Venketasubramanian N. rhage. Stroke. 2004;35:1415–1420.
Hypertensive basal ganglia hemorrhage: a prospective study comparing 195. Passero S, Burgalassi L, D’Andrea P, Battistini N. Recurrence of
surgical and nonsurgical management. Surg Neurol. 2001;56:287–292. bleeding in patients with primary intracerebral hemorrhage. Stroke.
172. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of
1995;26:1189 –1192.
intracerebral hemorrhage: a powerful and easy-to-use predictor of
196. Bae H, Jeong D, Doh J, Lee K, Yun I, Byun B. Recurrence of bleeding
30-day mortality. Stroke. 1993;24:987–993.
in patients with hypertensive intracerebral hemorrhage. Cerebrovasc
173. Ariesen MJ, Algra A, van der Worp HB, Rinkel GJ. Applicability and
Dis. 1999;9:102–108.
relevance of models that predict short term outcome after intracerebral
197. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo
haemorrhage. J Neurol Neurosurg Psychiatry. 2005;76:839 – 844.
JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ;
174. Cheung RT, Zou LY. Use of the original, modified, or new intracerebral
National Heart, Lung, and Blood Institute Joint National Committee on
hemorrhage score to predict mortality and morbidity after intracerebral
Prevention, Detection, Evaluation, and Treatment of High Blood
hemorrhage. Stroke. 2003;34:1717–1722.
Pressure; National High Blood Pressure Education Program Coordi-
175. Lisk DR, Pasteur W, Rhoades H, Putnam RD, Grotta JC. Early presen-
nating Committee. The Seventh Report of the Joint National Committee
tation of hemispheric intracerebral hemorrhage: prediction of outcome
on Prevention, Detection, Evaluation, and Treatment of High Blood
and guidelines for treatment allocation. Neurology. 1994;44:133–139.
Pressure: the JNC 7 report. JAMA. 2003;289:2560 –2572.
176. Rost NS, Smith EE, Chang Y, Snider RW, Chanderraj R, Schwab K,
198. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The
FitzMaurice E, Wendell L, Goldstein JN, Greenberg SM, Rosand J.
Prediction of functional outcome in patients with primary intracerebral effect of warfarin and intensity of anticoagulation on outcome of intra-
hemorrhage: the FUNC score. Stroke. 2008;39:2304 –2309. cerebral hemorrhage. Arch Intern Med. 2004;164:880 – 884.
177. Ruiz-Sandoval JL, Chiquete E, Romero-Vargas S, Padilla-Martínez JJ, 199. Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D,
González-Cornejo S. Grading scale for prediction of outcome in primary Moomaw CJ, Broderick JP, Woo D. Location and outcome of
intracerebral hemorrhages. Stroke. 2007;38:1641–1644. anticoagulant-associated intracerebral hemorrhage. Neurocrit Care.
178. Tuhrim S, Dambrosia JM, Price TR, Mohr JP, Wolf PA, Hier DB, Kase 2006;5:197–201.
CS. Intracerebral hemorrhage: external validation and extension of a 200. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can
model for prediction of 30-day survival. Ann Neurol. 1991;29:658 – 663. patients be anticoagulated after intracerebral hemorrhage? A decision
179. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Validation and com- analysis. Stroke. 2003;34:1710 –1716.
parison of models predicting survival following intracerebral hemor- 201. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term
rhage. Crit Care Med. 1995;23:950 –954. anticoagulation or antiplatelet treatment in patients with non-rheumatic
180. Tuhrim S, Horowitz DR, Sacher M, Godbold JH. Volume of ventricular atrial fibrillation. BMJ. 2001;322:321–326.
blood is an important determinant of outcome in supratentorial intrace- 202. ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH,
rebral hemorrhage. Crit Care Med. 1999;27:617– 621. Pfeffer M, Chrolavicius S, Yusuf S. Effect of clopidogrel added to aspirin
181. Naidech AM, Bernstein RA, Bassin SL, Garg RK, Liebling S, Bendok in patients with atrial fibrillation. N Engl J Med. 2009;360:2066–2078.
BR, Batjer HH, Bleck TP. How patients die after intracerebral hemor- 203. Goldstein LB, Amarenco P, Szarek M, Callahan A 3rd, Hennerici M,
rhage. Neurocrit Care. 2009;11:45– 49. Sillesen H, Zivin JA, Welch KM; SPARCL Investigators. Hemorrhagic
182. Zurasky JA, Aiyagari V, Zazulia AR, Shackelford A, Diringer MN. Early stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol
mortality following spontaneous intracerebral hemorrhage. Neurology. Levels study. Neurology. 2008;70:2364 –2370.
2005;64:725–727. 204. Woo D, Sauerbeck LR, Kissela BM, Khoury JC, Szaflarski JP, Gebel J,
183. Becker KJ, Baxter AB, Cohen WA, Bybee HM, Tirschwell DL, Newell Shukla R, Pancioli AM, Jauch EC, Menon AG, Deka R, Carrozzella JA,
DW, Winn HR, Longstreth WT Jr. Withdrawal of support in intracere- Moomaw CJ, Fontaine RN, Broderick JP. Genetic and environmental
bral hemorrhage may lead to self-fulfilling prophecies. Neurology. 2001; risk factors for intracerebral hemorrhage: preliminary results of a
56:766 –772. population-based study. Stroke. 2002;33:1190 –1195.
184. Zahuranec DB, Brown DL, Lisabeth LD, Gonzales NR, Longwell PJ, 205. Tsementzis SA, Gill JS, Hitchcock ER, Gill SK, Beevers DG. Diurnal
Smith MA, Garcia NM, Morgenstern LB. Early care limitations inde- variation of and activity during the onset of stroke. Neurosurgery.
pendently predict mortality after intracerebral hemorrhage. Neurology. 1985;17:901–904.
2007;68:1651–1657. 206. Chae J, Zorowitz RD, Johnston MV. Functional outcome of hemor-
185. Mirski MA, Chang CW, Cowan R. Impact of a neuroscience intensive rhagic and nonhemorrhagic stroke patients after in-patient rehabilitation.
care unit on neurosurgical patient outcomes and cost of care: Am J Phys Med Rehabil. 1996;75:177–182.
207. Kelly PJ, Furie KL, Shafqat S, Rallis N, Chang Y, Stein J. Functional 214. Schroeter S, Khan K, Barbour R, Doan M, Chen M, Guido T, Gill D,
recovery following rehabilitation after hemorrhagic and ischemic stroke. Basi G, Schenk D, Seubert P, Games D. Immunotherapy reduces
Arch Phys Med Rehabil. 2003;84:968 –972. vascular amyloid-beta in PDAPP mice. J Neurosci. 2008;28:
208. Schepers VP, Ketelaar M, Visser-Meily AJ, de Groot V, Twisk JW, 6787– 6793.
Lindeman E. Functional recovery differs between ischaemic and haem- 215. Morgenstern LB, Bartholomew LK, Grotta JC, Staub L, King M, Chan
orrhagic stroke patients. J Rehabil Med. 2008;40:487– 489. W. Sustained benefit of a community and professional intervention to
209. Hemphill JC 3rd, Farrant M, Neill TA Jr. Prospective validation of the ICH increase acute stroke therapy. Arch Intern Med. 2003;163:2198 –2202.
Score for 12-month functional outcome. Neurology. 2009;73:1088–1094. 216. Ratan RR, Siddiq A, Smirnova N, Karpisheva K, Haskew-Layton R,
210. Stroke Unit Trialists’ Collaboration. Organised inpatient (stroke unit)
McConoughey S, Langley B, Estevez A, Huerta PT, Volpe B, Roy S,
care for stroke. Cochrane Database Syst Rev. 2007:CD000197.
Sen CK, Gazaryan I, Cho S, Fink M, LaManna J. Harnessing hypoxic
211. Outpatient Service Trialists.Therapy-based rehabilitation services for
stroke patients at home. Cochrane Database Syst Rev. 2003:CD002925. adaptation to prevent, treat, and repair stroke. J Mol Med. 2007;85:
212. Zahuranec DB, Morgenstern LB, Garcia NM, Conley KM, Lisabeth LD, Rank 1331–1338.
GS, Smith MA, Meurer WJ, Resnicow K, Brown DL. Stroke health and risk 217. Zhao X, Grotta J, Gonzales N, Aronowski J. Hematoma resolution as a
education (SHARE) pilot project: feasibility and need for church-based stroke therapeutic target: the role of microglia/macrophages. Stroke. 2009;
health promotion in a bi-ethnic community. Stroke. 2008;39:1583–1585. 40(suppl):S92–S94.
213. Hawkes CA, McLaurin J. Selective targeting of perivascular macro- 218. He Y, Wan S, Hua Y, Keep RF, Xi G. Autophagy after experimental
phages for clearance of beta-amyloid in cerebral amyloid angiopathy. intracerebral hemorrhage. J Cereb Blood Flow Metab. 2008;28:
Proc Natl Acad Sci U S A. 2009;106:1261–1266. 897–905.

ICH Guidline AHA

Uploaded by

Copyright:

Available Formats

ICH Guidline AHA

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

ICH Guidline AHA

Uploaded by

Copyright:

Available Formats

AHA/ASA Guideline

Guidelines for the Management of Spontaneous

S pontaneous, nontraumatic intracerebral hemorrhage (ICH)

current work. The writing group met by phone to determine ED Management

Table 1. Applying Classification of Recommendations and Level of Evidence

evaluator the INR.39 – 41 The efficacy of FFP is limited by risk of allergic

Table 3. Class I Recommendations

surgical removal of the hemorrhage as soon as possible.

Table 4. Integral Components of the History, Physical Table 4. Continued

Initial symptoms and Urinalysis and urine culture

Dementia Associated with amyloid angiopathy Neuroimaging As described in the text

Plasma-derived serum factor VIII level by 2%

has not been clearly demonstrated.25,74

disease severity, comorbidities, and hospital characteristics.84

Figure. Intracranial pressure treatment

dence: C). (New recommendation)

Population-based studies of survivors of a first hemorrhagic

Writing Group Disclosures Continued

References W, Sartor K; Kompetenznetzwerk Schlaganfall B5. Stroke magnetic

primary intracerebral hemorrhage. AJNR Am J Neuroradiol. 2008;29:

Neurochir Suppl. 2006;96:65– 68. conservative therapy. Surg Neurol. 2006;65:67–72.

You might also like